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Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. 
patients with a metastatic PDAC only survive 3 – 5 months if left untreated and less than 25% 
of diagnosed patients are eligible for surgery. Radiation and chemo–therapy, improves 
survival by only a few months to live. Overall, the one–year survival is 20%, while the five–
year survival rate is a mere 5 – 7%. The poor prognosis of PDAC is predominantly due to the 
asymptomatic nature of the tumour in early stages. The PDAC tumour is known be severely 
hypoxic and desmoplastic making it particularly hard to treat. In spite of limited success in 
increased survival with the chemotherapy, the outcome is still not satisfactory. Clearly, there 
is a dire need for better and more efficient treatment options. Ultrasound (US) mediated 
cancer therapy with microbubbles, or sonoporation, is currently one of the emerging cancer 
treatments. 
 
The primary aim of this project is to elucidate the pathways activated by sonoporation in 
pancreatic cell lines by analysing post–translational modifications (i.e., phosphorylation). The 
long–term goal is to identify biomarkers for sonoporation that can be used to optimise 
sonoporation therapy. The pathways investigated were the Mitogen Activated Kinases 
(MAPKs) ERK 1/2, p38 and SAPK/JNK; the unfolded protein response (UPR) protein eIF2a; 
and the JAK/STAT pathway protein STAT3. Furthermore, ribosomal protein S6 of the PI3K-
mTOR pathway was investigated, in addition to MLC and MYPT1, which are regulators in 
the Rho/ROCK pathway. 
 
More specific aims were to: 
- Iinvestigate of protein signalling pathways activated by sonoporation in the AML cell 
line MOLM–13 
- develop methodology for in vitro optimisation of sonoporation 
- investigate the influence of sonoporation on cell viability 
- investigate protein signalling pathways activated by sonoporation in the pancreatic cell 
lines MIA PaCa–2, PANC-1 and BxPC-3  
 
Cells were treated using bespoke US treatment chambers designed for suspension or adherent 
cells. Adherent cells were treated in the bioreactor Petaka G3 LOT. Following sonoporation, 
cell viability was assessed using trypan blue (live/dead cell exclusion assay), Hoechst 33342 
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(apoptotic assay) and WST-1 (metabolic assay). Furthermore, phosphorylation status of 
selected signalling proteins in sonoporated cells were analysed by western blot. For pancreatic 
cell lines methodology was optimised, including viability assays, growth rate in Petakas, cell 
detachment, incubation time post sonoporation before protein extraction and, finally, western 
blotting was optimised by inducing phosphorylation to test the antibodies in aforementioned 
cell lines.  
 
Sonoporation–induced cell signalling was successfully detected using MOLM-13. Results 
showed that enzymatic cell detachment with pre-heated trypsin can influence cell signalling. 
Sonoporation of MIA PaCa-2 cells showed that the cells’ viability was affected at the higher 
US intensities without microbubbles, shown as decreased metabolic activity (WST–1), 
suggesting that US alone affects cell viability. Trypan blue showed a relative increase of 
trypan blue stained cells at low US intensity. Hoechst 33342 analysis showed a trend of 
decreasing number of dead cells with and without microbubbles with increasing US intensity, 
indicating that high US and microbubbles affects cell viability. In western blot analysis of the 
MAPKs, no phosphorylation of p38 or JNK was detected, however, there was an increasing 
phosphorylation of ERK 1/2. eIF2a, and STAT3 were phosphorylated in all samples, 
suggesting they are constitutively active in MIA PaCa-2. S6 was phosphorylated at the higher 
US intensities with microbubbles.  MLC, was phosphorylated at the highest US intensity with 
microbubbles, while MYPT1 was not phosphorylated.  
 
Methodology for in vitro optimisation of sonoporation was developed. Using this 
methodology, we have identified several pathways activated by sonoporation that may have 
potential as biomarkers for PDAC that can be used to optimise sonoporation therapy. It was 
also found that higher US intensities and microbubbles may have an effect of cell viability, 






1.1 Cancer  
Cancer is the second leading cause of death worldwide, responsible for 8.8 million deaths in 
2015 (2). The most common causes of cancer death are cancers of lung, liver, colorectal, 
stomach and breast (2). In 2012 an estimated 14.1 million new cancer cases occurred and the  
burden of cancer is expected to increase to 23.6 million new cases each year by 2030 (3).  
Although incidence of other cancers is higher, pancreatic ductal adenocarcinoma (PDAC) is 
currently one of the most lethal cancers worldwide. Patients with locally advanced PDAC 
have a median survival of 6 –10 months, and patients with a metastatic PDAC only survive 3 
– 5 months if left untreated. Less than 25% of diagnosed patients are eligible for surgery, 
which gives the patient the best chance of survival. That leaves radiation and chemo–therapy, 
which, at best, provides the patient with a few additional months to live. (4). Only 20% of 
PDAC patients survive one year after initial diagnosis, while the five–year survival rate is a 
mere 5 – 7% (5). Furthermore, survival rates for pancreatic cancer has not changed during the  
Figure 1: Trends cancer survival rates as a function of time (6). Pancreatic cancer has the lowest 
survival of all 21 common cancers, reflected in the minor increase in survival from 2% in 1971 to 3% 
in 2011). Survival rates for other common cancers have increased by up to 37%. 
 
past five decades, while for other common cancers it has increased significantly (7) (Figure 
1). In the UK the survival rates for pancreatic cancer has only shown an increase of 1%, from 
2% in 1971 to 3% in 2011. In contrast,  the survival rates for other cancer have increased by 
up to 37% (6) (Figure 1). 
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1.1.2 PDAC characteristics 
The poor prognosis of PDAC is predominantly due to the asymptomatic nature of the tumour 
in early stages. Typically, by the time the tumour is discovered it has encased major vessels 
surrounding it and metastasized (5). Tumours grow rapidly, compared to non–cancerous cells, 
and when the tumour grows beyond 1 – 2  mm in diameter the majority of cells are too far 
away from the regular vasculature to take advantage of the oxygenated blood, resulting in a 
severely hypoxic tumour micro environment (TME) (8).  The hypoxic TME triggers hypoxia–
inducible factor (HIF), which initiate angiogenesis, and a number of growth factors. Chronic 
inflammation is sustained in the tumour by many factors, including cytokines, growth factors, 
which are produced in excess, leading to the irregular growth of tumour vasculature. The 
irregularity of the tumour vasculature contributes to the highly hypoxic TME (9). 
Furthermore, increased permeability of tumour neovasculature, caused by loss of cellular 
junction integrity and increased production of VEGF, and the lack of tumour lymphatic 
system, in addition to chronic inflammation all contribute to accumulation of fluid in the 
interstitium, resulting in increased tumour interstitial fluid pressure (TIFP). Another factor 
contributing to the build–up of fluids in the interstitium is a decreased hydrostatic pressure in 
the tumour vasculature, as well as elevated osmotic pressure in the interstitium, which results 
in stagnant blood flow. The increased tumour blood viscosity further aggravates perfusion 
(10). Perfusion is also repressed by pressure from the fibrous extracellular matrix (ECM) 
protein collagen, which is overexpressed in tumours (11, 12). Tumour heterogeneity of 
genetic mutations, plasticity, elevated TIFP and extreme desmoplasia lowers the efficacy of 
drug delivery may and render PDAC tumours resistant to chemotherapeutics, leading to poor 
response to treatment (4, 5, 13). KRAS gene mutations, which are found in 80% of PDAC 
patients, not only contributes to the promotion of tumour development and progression by 
stimulating growth factor receptors to initiate malignant transformation of pancreatic ductal 
epithelial cells, but also obstructs delivery of traditional chemotherapy (13). 
 
1.1.3 Current treatments and limitations 
From 1997 until 2011 Gemcitabine was the standard first–line chemotherapeutic treatment for 
metastatic PDAC (14).  In 2011 the FOLFIRINOX regimen (5–fluorouracil, oxaliplatin, 
irinotecan, and leucovorin) proved superior to Gemcitabine in terms of overall survival (OS) 
with an OS of 6.8 months versus 11.1 months for FOLFIRINOX versus Gemcitabine treated 
patients, respectively (15). In spite of adverse effects of the FOLFIRINOX treatment it 
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emerged as the new standard chemotherapy for metastatic PDAC (14). Gemcitabine has been 
combined with other cytotoxic drugs, such as irinotecan, capecitabine, 5–fluorouracil, 
cisplatin, oxaliplatin and capecitabine without any significant survival advantages, compared 
to Gemcitabine alone (14). However, nab–paclitaxel, an albumin–bound nanoparticle linked 
with paclitaxel, combined with Gemcitabine has proven to have a synergistic effect (16-18). 
The combination treatment  nab–paclitaxel plus Gemcitabine is currently the first–line 
treatment of metastatic pancreatic cancer (19). Treatment with FOLFIRINOX  and the 
combination therapy Gemcitabine plus nap–paclitaxel has had limited success increasing 
survival in patients, however, the outcome is still not satisfactory (14, 16-19). Clearly, there is 
a dire need for better and more efficient treatment options. Ultrasound (US), used for clinical 
imaging for half a century, is considered safe to use in humans, and microbubbles (MBs) has 
been used as a contrast agent to enhance the signal–to–noise ratio of the vasculature (4, 20).  
US mediated cancer therapy with MBs, or sonoporation, is currently one of the emerging 
treatments (21).  
 
1.2 Background Sonoporation 
1.2.1 Ultrasound 
US has been used for imaging purposes clinically for over 50 years and is considered a safe 
imaging modality and has for the past 30 years been used as a diagnostic tool to detect PDAC 
(4). Stabilised gas MBs are used as a contrast agent for diagnostic US imaging to enhance the 
signal–to–noise ratio of the vasculature, resulting in better images of tissue perfusion (4). The 
US can be aimed at a specific area, such as a tumour, with millimetre precision, which is an 
advantage when targeting diseased tissues during therapy (22). The US intensities used in 
diagnostic US range between 17 mW/cm2, for treatment of the eye, to 720 mW/cm2 used for 
peripheral vessels (23). 
 
1.2.2 Microbubbles 
The commercially available MBs are typically gas–filled (perfluorocarbon) bubbles stabilized 
by a monolayer phospholipid shell, approximately 2 – 10 µm in size (24). The hydrophilic 
head of the phospholipid face the water (outside) and the hydrophobic tail face the gas inside 
the MBs (25) (Figure 2). Clinically approved MBs include Optison (GE Healthcare, Little 
Chalfont, England) which has a cross–linked serum albumin shell filled with 
octafluoropropane gas, and Sonazoid (GE Global Healthcare, Little Chalfont, United 
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Kingdom)  and SonoVue® (Bracco, Italy) both consisting of a phospholipid monolayer, filled 




Figure 2: Typical microbubble composition. The gas filled microbubbles consists of a monolayer of 
phospholipids. The MB size range from 0.5 – 10 µm. The hydrophilic heads face outwards towards the 
water, while the hydrophobic tails face in towards the gas.  
 
 
1.2.3 The mechanisms of sonoporation 
When exposed to US, MBs volumetrically oscillate, creating stable or inertial cavitation 
(Figure 3). Low intensity US (LIUS) causes stable cavitation, which is a result of stable, 
symmetrical oscillation of the MBs. During stable cavitation the compression and expansion 
(rarefaction) of the MBs are inversely proportional to the US pressure (Figure 3B). 
Conversely, when the MBs are exposed to high intensity US (HIUS), inertial cavitation 
occurs. A lengthening of the expansion phase enlarges the MBs, eventually resulting in 
implosion (27) (Figure 3C). The MBs generate their own ultrasonic pulse when the US wave 
hits the MBs scattering the incoming US (24). When the MBs are in close vicinity of cells as 
they are exposed to US the cells experience sheer stress, which may induce a wide range of 
mechanical and biological effects in addition to creating pores (27) (Figure 3D–H). The 
oscillating MBs interact with the plasma membrane in many ways (Figure 3). A stable 
cavitating MB push and pull the plasma membrane during the expansion and compression 






Figure 3: Biophysical effects of stable and inertial cavitating microbubbles. Figure adapted from (24). 
(A) Schematic representation of an acoustic pressure wave. (B) Stable cavitation of microbubbles 
caused by low intensity ultrasound. (C) Inertial cavitation of microbubbles caused by high intensity 
US. The effects of stable cavitation on the cell membrane are illustrated in (D), (F), while the effects 
of inertial cavitation are demonstrated in (G) and (H). The push and pull from a stably oscillating 
microbubbles disturb the cell membrane integrity (D). Acoustic radiation force displaces the 
microbubble against the cell membrane causing membrane disruption (E). Microstreaming created by 
the stably oscillating microbubbles create mechanical stress on the cell membrane, causing pore 
formation (F). Collapse of inertial cavitating microbubbles creates shock waves generating high 
stresses on the cell membrane, resulting in membrane disruption (G). A liquid jet is formed when a 
microbubble collapses near the cell surface puncturing the cell membrane (H).    
 
How close the MB has to be to the cell to cause pore formation has been studied in single–cell 
experiments. One study concluded that membrane perforation occurred with 75% probability 
when bubble–cell distance was equal to 75% of the maximum bubble radius (28). The size of 
the pores and how long it takes for the pore to close depends on the intensity of the US wave 
(mW/cm2) and the time exposed to US (28). That being said, pore sizes have been measured 
to be from 10 nm to 1 µm in size and occur within several to tens of microseconds. It is 
reported that the pores last from minutes up to a few hours (28). Pores can also be created by 
the force of the US wave pushing the MBs against the plasma membrane (acoustic radiation 
force) disrupting it, and the MB may even be pushed inside the cell (Figure 3E). A stable 
cavitating MB also create microstreaming in the fluid surrounding the cell causing mechanical 
stress on the plasma membrane, which can result in pore formation (Figure 3F). The 
implosion of MBs (following inertial cavitation) also creates pores due to the high stress on 
the plasma membrane (Figure 3G). Moreover, an imploding MB creates a liquid jet towards 






Lentacker et al (2014) 
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1.2.5 Intracellular effects of sonoporation 
 
 
Figure 4: Intracellular effects of stably and inertial cavitating microbubbles. Adapted from (27). Pore 
formation allows molecules, such as calcium (Ca2+) and drugs, to passively diffuse into the cell (A). 
Microbubble cavitation causes production of reactive oxygen species (ROS), which can modulate ion 
channels or cause membrane disruption via lipid peroxidation. Hyperpolarization of the cell membrane 
can be caused by potassium efflux via Ca2+–dependent potassium (BKCa) channels due to Ca2+ influx 
mediated by ROS. Also, Ca2+ influx can stimulate endocytosis (B). The cell membrane can be 
deformed by the microstreaming generated by stably cavitating microbubbles, leading to cytoskeletal 
rearrangements and differences in membrane tension. The changes in membrane tension are detected 
by mechanosensors, which can initiate a signalling cascade that influences endocytosis/exocytosis 
processes (C). 
 
The creation of pores in the plasma membrane creates a range of biological effects. Pores 
enables membrane impermeable molecules such as Calcium (Ca2+) and drugs to diffuse 
passively into the cell (27, 28) (Figure 4A–B). The stress on the cell created by a cavitating 
MBs creates reactive oxygen species (ROS), which are involved in modulation of ion–
channels. The production of ROS can also lead to lipid peroxidation which causes membrane 
disruption. As a result of Ca2+ influx mediated by ROS potassium (K+) diffuse out of the cell 
via Ca2+–dependent potassium (BKCa) channels, which results in hyperpolarization of the 
plasma membrane (Figure 4B). Moreover, Ca2+ influx stimulates endocytosis (Figure 4). 
Further biological effects from stably cavitating MBs include cytoskeletal rearrangements and 
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differences in membrane tension as a result of deformation of the membrane caused by sheer 
stress. The deformation of the membrane is sensed by mechanosensors, such as integrins and 
stretch-activated ion channels, which transduce these signals into downstream processes such 
as endocytosis and exocytosis processes (27) (Figure 4C). In addition to pores created by 
membrane perforation the oscillating MB can create gaps between cells, so–called 
interendothelial gaps, in the blood vessels (28) (Figure 5).  
Figure 5: Passive and active delivery routes enhanced by sonoporation. Figure adapted from (2). 
Sonoporation perforates the membrane by acoustic cavitation allowing passive diffusion of 
macromolecules into the cell. The interendothelial junction may be opened by acoustic cavitation, 
providing an active route for macromolecules and drugs.  Stable cavitation stimulates endocytosis, 
actively delivering macromolecules into the cells via vesicles.  
 
Pore formation and interendothelial gaps creates a “drug delivery route” bypassing the 
abnormal tumour vasculature that normally hinders drug distribution to large areas of the 
tumour (8) (Figure 5). However, the creation of pores allow for deeper drug penetration, 
hopefully increasing the efficacy of the drug (4). Due to the many challenges of treating 
PDAC, including late detection due to its asymptomatic nature (5), extreme hypoxic (9) and 
desmoplastic nature (4), elevated TIFP and increased tumour blood viscosity (10), surgery is 
not possible for most patients (85%) (4), thus, there is a dire need for improved drug delivery 
for treatment of PDAC.  
 
1.2.6 Previous research 
The biomechanical mechanisms of sonoporation are thoroughly studied (27-29), however, the 
intracellular effects are not well documented. One study found that apoptosis–related proteins 
in sonoporated leukemia cells (HL–60) and found a reduction in poly adenosine diphosphate 
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ribose polymerase (PARP) signalling and a simultaneous increase in cleaved–PARP, and B–
cell lymphoma 2 (Bcl–2) had a decreased signal following sonoporation, while Bcl–2–
associated X (Bax) had a slight increased signal. These results indicate that these proteins 
have an active role in sonoporation–induced apoptosis (30). The effect of clinical US in 
leukaemia cells (MOLM–13) and monocytes have been found to react differently to US. 
MOLM–13 had increased signalling of p38 when exposed to US (161 mW/cm2) plus MBs, 
while the monocytes had an increased signal at all US intensities (0.35, 1.17 and 161 
mW/cm2) plus MBs, but also at high US without MBs. Extracellular signal–regulated kinases 
1 & 2 (ERK 1/2) had an overall increase in signal in MOLM–13 cells, but the signalling 
monocytes were downregulated (20). The endoplasmic reticulum (ER)–stress response has 
been found to be induced in HL–60 leukemia cells by sonoporation. The ER–stress sensors 
PKR–like ER kinase (PERK) and  inositol–requiring enzyme 1 (IRE1) was activated upon 
exposure to sonoporation with increasing signal in a time–dependent manner (31).  
 
1.2.7 Choice of signalling pathways 
1.2.7.1 Unfolded protein response 
Cell signalling induced by sonoporation is largely untouched territory and there are nearly 
limitless signalling pathways and signalling proteins to investigate. ER–stress has been shown 
to be induced in leukaemia cells by sonoporation (31), however, assessment of 
phosphorylation status of ER–stress proteins was not included. ER–stress can be induced by 
various biochemical, physiological, pathologic and mechanical stresses leading to oxidative 
stress, altered glycosylation, DNA damage and energy disturbance/ fluctuation, nutrient 
deprivation and Ca2+ depletion (32). ER–stress is sensed by three ER–transmembrane 
receptors; IRE1, PERK, and activating transcription factor 6 (ATF6), which triggers the 
unfolded protein response (UPR) (33) (Figure 6). One of the downstream signalling proteins 
of PERK is the eukaryotic initiation factor 2a (eIF2a). Upon phosphorylation eIF2a initiates 
a signalling cascade resulting in decreased global protein translation via amplification of the 
selective translation of the mRNA encoding for ATF4 (Figure 6). ATF4 is a transcription 
factor that induces the expression of genes involved in amino acid metabolism, autophagy, 
apoptosis, antioxidant responses and GADD34. Under prolonged ER–stress PP1C, encoded 
by GADD34, dephosphorylates eIF2a counteracting PERK activity (33) (Figure 6). 
Attenuation of global protein translation have a significant adverse effect on cellular survival 




Figure 6: The unfolded protein response (UPR) signalling. Figure adapted from (33). The stress 
sensors IRE1, PERK, and ATF6 regulates the UPR. Activation of PERK phosphorylates eIF2a 
leading to attenuation of global protein synthesis via activation of the transcription factor ATF4, which 
induces the expression of genes involved in antioxidant responses, apoptosis, amino acid (AA) 
metabolism, autophagy, and GADD34. Under sustained ER–stress GADD34 feeds back to 
dephosphorylate eIF2a. ER–stress leads to dimerization and autophosphorylating of IRE1, which 
activates its endoribonuclease activity in the cytosolic domain. Active IRE1 modulates the processing 
of the mRNA encoding XBP1 (transcription factor), leading to upregulation of UPR target genes 
related to folding, quality control, and ER–associated degradation (ERAD). Furthermore, IRE1 
degrades certain mRNAs through regulated IRE1–dependent decay (RIDD). During ER–stress, ATF6 
is processed at the Golgi apparatus, where the cytosolic domain is released and then translocate to the 
nucleus increasing the expression of some ER chaperones, ERAD–related genes, and XBP1. See text 
for definitions of abbreviations. 
 
1.2.7.2 MAPK pathway 
The UPR may also interact with the mitogen activated protein kinase (MAPK) pathway, a 
highly conserved family of serine/threonine protein kinases involved in a variety of 
fundamental cellular processes. MAPKs include ERK1/2, Stress–Activated Protein 
Kinase/Jun–amino–terminal Kinases (JNKs) and the p38 family (Figure 7). ERK 1/2 
regulates cell proliferation, differentiation and survival. The JNKs can mediate apoptosis and 
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autophagy, but also cell survival. Depending on the type of activation (mechanical, 
biochemical, physiological) activation of p38 can induce both cell proliferation and cell cycle 
arrest (35). In cancer, on the one hand, the initiation of the UPR can restore tumour 
homeostasis and enhance tumour growth. On the other hand, it can also lead to apoptosis (32). 
Since ER–stress can be induced by sonoporation (31), and ERK 1/2 and p38 have been found 
to be activated by sonoporation with MBs in leukemia cells (20). The involvement of eIF2a 
and the MAPKs in survival and apoptotic pathways makes them interesting targets in the 
investigation of the effect of sonoporation-induced signalling. 
 
 
Figure 7: Mitogen Activated Protein Kinase (MAPK) signalling – Cross–talk with the Unfolded 
Protein Response (UPR). Figure adapted from (35-39). Schematic of JAK/STAT, PI3K, MAPK and 
UPR signalling with points of cross–talk. Growth factors, hormones and integrins stimulate receptor 
tyrosine kinases (RTKs), which again activates the JAK/STAT pathway and the PI3K pathway 
upstream of ribosomal protein S6 (S6). There is cross–talk between the PI3K and MAPK pathway. 
PI3K can be activated by Ras and inhibited by ERK 1/2. Oncogenic Ras can also directly activate 
S6K. Akt can inhibit RAF, and ERK 1/2 can activate mTOR. The MAPK signalling pathways are 
activated by extracellular signals, such as ER–stress (and other cellular stresses), cytokines and growth 
factors, which activates MKKKs, MKKs and then MAPKs. Under ER–stress conditions the UPR 
activates ASK1–MKK4/7–JNK signalling and correspondingly promotes ERK1/2 activation. 
Furthermore, MEKK4–MKK3/4/6–p38 signalling also modulates the UPR via p38–dependent 
phosphorylation of CHOP and ATF6 (not shown). 
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1.2.7.3 JAK/STAT pathway 
Signal Transducers and Activators of Transcription 3 (STAT3) is a constitutively active 
transcription factor in many cancers, including haematological malignancies and pancreatic 
cancer, which promote angiogenesis, survival, immune evasion, cell proliferation and 
migration/invasion (Figure 7). STAT3 is an interesting therapeutic target because by 
blocking downstream STAT3 signalling tumour progression has been successfully 
inhibited (40). Several factors contribute to STAT3 activation in cancer, including 
overexpression of protein tyrosine kinases, epigenetic modulation of negative regulators 
of STAT3 and increased secretion of growth and cytokines factors in the tumour 
microenvironment (41). In relation to sonoporation, it would be interesting to see whether 
the constitutively active STAT3 is influenced by the US and MB treatment.  
 
1.2.7.4 PI3K-mTOR pathway 
Ribosomal protein S6 (S6) is a downstream substrate in the phosphatidylinositol 3–kinase 
(PI3K)–mammalian target of rapamycin (mTOR) pathway  (39) (Figure 7). PI3K is activated 
directly by growth factor receptors, or indirectly by insulin receptor substrate (IRS) or 
(GRB2–associated binder (GAB) docking proteins (not shown) (39). The mTOR complex 1 
(mTORC1) is activated via PI3K and Akt/PKB (Figure 7), and by energy status, amino acid 
levels and cellular stress through a number of phosphates and kinases. mTORC1 complex 
phosphorylates eukaryotic initiation factor 4E (eIF4E)–binding protein (4E–BP) and S6K 
(p70 ribosomal S6 Kinase), leading to activation of several downstream substrates, including 
S6 (Figure 7). Phosphorylation of S6 mediates proliferation, translation, survival and growth 
(39). Figure 7 shows cross-talk between the PI3K-mTOR and MAPK pathway (42). Ras can 
directly activate both PI3K and S6K (Figure 7). Considering the interconnecting links 
between the UPR, MAPK and PI3K-mTOR pathway, and as sonoporation has been shown to 









1.2.7.5 Rho/ROCK pathway 
Myosin Light Chain 2 (MLC2) and myosin–binding subunit of myosin phosphatase 1 
(MYPT are part of the Rho/Rho–associated coiled–coil–forming kinase (ROCK) 
signalling pathway that regulates the cytoskeleton. Actin–myosin contractions enables the 
cells to change shape and move during development, but also in inflammation and wound 
healing (43) (Figure 8). More specifically, what enables cells’ motility is the assembly of 
integrins in the plasma membrane forming focal adhesions, not only enables locomotion, 
Figure 8: Rho/ROCK pathway simplified. Figure adapted from (44). lysophosphatidic acid (LPA) or 
sphingosine–1–phosphate (S1P) binds to G–protein–coupled receptors (GPCRs), which activates 
Guanine nucleotide exchange factors (GEFs). GEFs phosphorylate Rho Kinase (Rho), while GTPase 
activating proteins (GAPs) dephosphorylate Rho. GTP–bound Rho subsequently activates Rho–
associated coiled–coil–forming kinases (ROCKs) to phosphorylate myosin light chain (MLC). MLC 
phosphatase (MLCP) consists of the myosin–binding subunit myosin phosphatase target subunit 
(MYPT1), the catalytic subunit protein phosphatase type 1 (PP1c) and a small non–catalytic subunit of 
unknown function. De–phosphorylation of MYPT by ROCKs inhibits the dephosphorylation of MLC, 
thereby increasing myosin II activity and stress–fibre formation and contractility. MLCP 
dephosphorylates MLC. Abbreviation: Guanosine–5'–triphosphate (GTP).  
 
but strengthens the cells ability to resist mechanical injury. The Rho/ROCK pathway 
regulates this focal adhesion assembly by activation of Rho and ROCK. In fact, sonoporation 
(mechanical stress), has been shown to affect the cytoskeleton (45, 46) (Figure 8). ROCK 
inhibits MLC phosphatase (MLCP), thereby promoting phosphorylation of MLC (47). 
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Furthermore, Rho/ROCK, which also mediates cytoskeletal reprogramming during invasion 
and metastasis, is activated by hypoxia–inducible factors 1 (HIF–1) and 2 (HIF–2) in cancer 
(48). Since pancreatic cancer is known to be severely hypoxic (49), it would be interesting to 
investigate the role of MLC2 and MYPT1 in pancreatic cell lines. De–regulation of for 
example small GTPases (RhoA) and kinases, such as ROCK1/2 in cancer further contribute to 
the invasive behavior of cancers (43). MYPT1 is one of three sub–regulatory units of MLCP, 
the second is the catalytic subunit protein phosphatase type 1, (PP1c), and the third is a small 
a small non–catalytic subunit of unknown function (44) (Figure 8). The GTP–bound Rho 
activates ROCKs, which phosphorylate MLC. Phosphorylation of MYPT by ROCKs, 
however, inhibits the dephosphorylation of MLC, thus increasing myosin II activity and 
stress–fibre formation and contractility (44) (Figure 8). Both the amino terminus and the 
carboxyl terminus of MYPT have a binding site for myosin. Also, the amino–terminal of 
MYPT binds PP1c, and the carboxy–terminal half contains binding sites for the small non–
catalytic subunit and RhoA. Phosphorylation of residues in the carboxy–terminal results in the 
inhibition of MLCP activity and a concomitant increase in phosphorylated MLC and cell 
contractility. ROCK II phosphorylates MYPT at Thr697, Ser854 and Thr855. The ROCK II–
mediated phosphorylation of Thr855 induces its dissociation from myosin, which might 
inhibit myosin phosphatase activity. Thr697 phosphorylation is also implicated in the 
inhibition of MLCP activity, but how this regulates the catalytic activity of PP1c is unknown 
(44). In relation to sonoporation, it would be very interesting to see whether sonoporation 
affects for example cancer cells invasive behaviour via the Rho/ROCK pathway. 
 
1.3 Preclinical results 
Sonoporation used to increase drug uptake is a growing area of research (50), and has been 
tested in multiple animal models. One group demonstrated that local sonoporation to the 
kidney transiently affected the glomerular filtration barrier resulting in increased the transfer 
of oligonucleotides in mice (51). Another group, studying oral squamous cell carcinoma in 
hamster models, found that the chemotherapeutic carboplatin combined with low intensity US 
had a synergetic effect enhancing the effect of the drug, prolonging survival and had no 
additional side–effects (52). Furthermore, in a study performed with a rat pancreas carcinoma 
model, treated with drug loaded MBs and US, resulted in a 12–fold higher drug tissue 
concentration and a significantly lower tumour growth, compared to the control (53). Studies 
performed at the University of Bergen (UIB) have investigated the effect of treating PDAC 
with US and MBs, in addition to a chemotherapeutic agent, in an orthotopic xenograft mouse 
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model of luciferase expressing the pancreatic cell line MIA PaCa–2. The mice were divided 
into a control group (saline treatment only), one group was treated with gemcitabine alone, 
and one group was treated with Gemcitabine combined with US and SonoVue® MBs. 
Sonoporation was induced in a localized region of the primary tumour with a custom–made 
focused US transducer using clinically safe acoustic conditions. In the combination group the 
tumour growth was significantly inhibited, compared to the control and the group treated with 
gemcitabine only, indicating improved uptake in the combination group (24). 
 
1.4 Clinical trials 
These promising results led to the world first phase I clinical trial testing Gemcitabine 
combined with LIUS and SonoVue® MBs (21). Other groups have investigated the effect of 
HIUS on drug uptake (54), however, LIUS in combination with a chemotherapeutic agent had 
not yet been tested in humans before (4). In this trial, ten terminally ill PDAC patients were 
treated with Gemcitabine plus LIUS and MBs (SonoVue®), compared to historical controls 
having received gemcitabine monotherapy. One of the aims of the study was to evaluate the 
safety and potential toxicity of gemcitabine combined with sonoporation in inoperable 
pancreatic cancer patients. No additional toxicity or increased frequency of side effects were 
found, and the patients tolerated an increased number of gemcitabine cycles compared to the 
historical control (Control: n = 63 patients; average of 8.3 ± 6.0 cycles, versus sonoporation + 
gemcitabine–treated patients: 13.8 ± 5.6 cycles, p = 0.008, unpaired t–test). The median 
survival of the patients increased from 8.9 months to 17.6 months (p =0.011). The study 
concluded that “it is possible to combine ultrasound, microbubbles, and chemotherapy in a 
clinical setting using commercially available equipment with no additional toxicities. This 
combined treatment may improve the clinical efficacy of gemcitabine, prolong the quality of 
life, and extend survival in patients with pancreatic ductal adenocarcinoma” (4).  
 
Another phase 1 trial has successfully disrupted the blood brain barrier with pulsed US and 
microbubble treatment. An US device system (SonoCloud) was implanted in in patients with 
recurrent glioblastoma, which was treated monthly using pulsed US in combination with 
systemically injected microbubbles followed by systemic infusion of the chemotherapeutic 
carboplatin. They reported that the treatment was found to be safe and well tolerated by 




The evidence that sonoporation has potential to improve drug delivery is growing, however, 
the intracellular mechanisms behind slowed tumor growth and increased tolerance of 
chemotherapy in PDAC is largely unknown.  
 
1.5 Choice of cell lines 
Several in vitro sonoporation studies have been performed with leukemia cells (20, 30, 31, 
56), which are suspension cells, making them easier to work with, compared to adherent cells. 
However, the main objective of this project was to investigate the effect of sonoporation on 
post translational modifications of proteins (i.e., phosphorylation) in adherent pancreatic cell 
lines. Therefore, the initial testing was done with the leukemic cell line MOLM–13. To get a 
good representation of patient heterogeneity three pancreatic cell lines MIA PaCa–2, PANC–
1 and BxPC3 were included. MIA PaCa–2 and PANC–1 differs in morphology and 
immunohistochemistry, expresses polymorphism and pleomorphism, respectively. One 
similarity between two of the cell lines is that both have epithelial–mesenchymal transition 
(EMT) differentiation. However, PANC–1 does not express E–cadherin, making it more 
aggressive in terms of metastasis (57). The three cell lines differ in origin adhesiveness, 
invasiveness, genotype and angiogenic potential (58) 
 
1.6 Ultrasound treatment of cell culture 
1.6.1 Challenges 
To treat cells with US can be a challenge since there are many parameters that needs to be 
optimised. In addition, cell signalling cascades are very sensitive and can be induced by 
reagents, such as heated trypsin–EDTA (37oC) used to detach adherent cells (59, 60), and by 
mechanotransduction triggered by handling the cells (61). Trypsin–EDTA is discussed in 
chapter 1.6.4. 
 
1.5.3 Adherent cells 
The PDAC tumour is known to be severely hypoxic, therefore, in order to study the PDAC 
cell line MIA PaCa–2 cells in a similar hypoxic environment, the low oxygen transfer 
bioreactors called “Petaka G3” was used to culture PDAC cell lines as PDAC tumours.  
There is no research done on the treatment of pancreatic cells with US in a Petaka. Therefore, 





1.6.4 Cell detachment in Petaka 
In order to study cell signalling in adherent cells, they need to be detached. The commonly 
used cell detachment method of cell scraping is possible using a magnet (62), however, due to 
the lack of necessary equipment to implement this, enzymatic cell detachment was used in 
this project. Trypsin is a proteolytic enzyme, used to detach cells from the substrate, that 
detaches the cells by cleaving peptides at the C–terminal side of arginine and lysine amino 
acid residues and works optimally when heated to 37oC (physiologic temperature) (60). 
However, trypsin heated to 37oC may affect the integrity of cell surface proteins (60) . 
Trypsin is available in different concentrations. To detach strongly adherent cell lines trypsin 
from 2.5% to 0.25% (10×  to 1×  power, respectively) are used (60). To increase the 
enzymatic activity disodium ethylenediaminetetraacetic acid (EDTA) is added to the trypsin 
solution. EDTA works as a chelating agent neutralizing calcium and magnesium ions that 
obscure the peptide bonds on which trypsin acts (63). The 10× trypsin used in this project did 
not have EDTA added. In this thesis “trypsin” refers to the “trypsin–EDTA” solution, unless 
otherwise stated. Trypsin has been identified to activate cell signalling via the G protein–
coupled receptor protease–activator receptor 2 (PAR2) by cleaving the amino–terminal 
exodomain. In epithelial and smooth muscle cells PAR2 activation stimulates the MAPK 
pathway, and trypsin activated PAR2 may also activate MAP phosphatase activity and reduce 
phosphorylated–ERK 1/2 (p–ERK 1/12) level induction by other receptors (59). Furthermore, 
one study determined that trypsin induced RhoA signalling (64). At a temperature of  4oC 
trypsin is still  50% active, but the tyrosin kinases remain inactive (59). Thus, test cell 
detachment with ice–cold trypsin was tested to see if the phosphorylation status of the 
proteins of interest differ between regular warm (37oC) and cold trypsinization. 
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1.7 Western Blot 
WB, also called immunoblotting, is the gold standard of identifying presence or absence of a 
protein in a biological sample, and for detecting change in posttranslational modifications (i.e, 
phosphorylation/de–phosphorylation, acetylation, methylation, and ubiquitination) by 
antibody (Ab) binding to a specific protein of interest (1). A simplified overview of WB is 
explained in Figure 9. Protein is extracted from tissue or cells and protein concentration is 
quantified before preparing the samples by adding loading dye and denaturing the proteins by 
heating them. The loading dye contains sodium dodecyl sulfate (SDS), which is a strong 
anionic detergent added to coat hydrophobic regions of proteins with negative charge, thus 
overpowering positive charges in proteins, which endures a uniformly distributed negative 
Figure  9: Sequential stages of the Western 
blot process. Figure adapted from (1). 
Extraction of cellular proteins from cells (1); 
quantification of protein concentration and 
electrophoretic separation of proteins within a 
gel matrix (2); transfer to a membrane with a 
high affinity for proteins (3); “blocking” the 
membrane to reduce non-specific binding (4); 
antigen detection by antibodies specific for the 
protein(s) of interest (5); incubation with a 
secondary antibody linked to a label (e.g., 
chemiluminescent or fluorescent) (6); 
development and detection of the signal, which 
is theoretically proportional to the degree of 
antigen/antibody binding and quantification of 





charge of the protein lysate (64). The loading dye also contains glycerol, which makes the 
sample heavier than the running buffer surrounding the gel, thereby ensuring that the sample 
collects at the bottom of the well. The protein samples are separated during gel 
electrophoresis based on size and electric charge, then transferred to a membrane with high 
affinity for proteins. The membrane is then incubated in a blocking buffer, which contains a 
5% membrane-blocking agent in Tris-buffered saline and  0.05% Tween 20, which aids in the 
removal of residual SDS from earlier steps. The blocking buffer also improve the sensitivity 
of the assay by reducing background interference and improving the signal-to-noise ratio. 
After blocking, the membrane is incubated with antigen-specific primary antibody, typically 
over-night, after which the membrane is washed with purified water and blocking buffer to 
remove residual primary Ab. The next step is incubation with secondary antibody, which is 
conjugated to a chemiluminescent or fluorescent protein. After further washing steps the  
signal (phosphorylation), which is theoretically proportional to the degree of antigen/antibody 
binding, can be detected and quantified based on protein bands using densitometry software. 
A dark band means you have higher expression of protein or a stronger phosphorylation, 









The primary aim of this project is to elucidate the pathways activated by sonoporation. The 
goal is to identify biomarkers for PDAC that ca be used to optimise sonoporation therapy. 
 
The specific objectives were to 
- develop methodology for in vitro optimisation of sonoporation 
- do initial investigations of protein signalling pathways activated by sonoporation in 
the AML cell line MOLM–13 
- investigate protein signalling pathways activated by sonoporation in the pancreatic cell 




3.0 Materials and Methods 
All reagents were purchased from Sigma–Aldrich (Inc. St Louis, MO, USA) unless otherwise 
stated.  
 
3.1.1 Cell culturing 
The acute myeloid leukemia (AML) cell line MOLM–13 was purchased from DSMZ, 
(Deutche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, 
Germany) and maintained in Roswell Park Memorial Institute (RPMI) –1640 medium 
supplemented with 1% (v/v) L–glutamine solution (L–G) and 10% (v/v) heat–inactivated fetal 
bovine serum (FBS).  
The pancreatic cell lines were kindly provided by Anders Molven laboratory at the University 
of Bergen and were originally purchased from ATCC® Europe (Wesel, Germany). MIA 
PaCa–2 cells originates from a 65–year–old male Caucasian and were cultured in Dulbecco's 
Modified Eagle's Medium – High glucose (DMEM) supplemented with 2.5 % (v/v) horse 
serum (HS; GibcoTM by Thermo Fisher Scientific, Waltham, MA, USA), 2% (v/v) L–G, 10% 
(v/v) FBS and 1% (v/v) Sodium Pyruvate (GibcoTM by Thermo Fisher Scientific, Waltham, 
MA, USA). The BxPC–3 epithelial cells originate from an adenocarcinoma tumour from a 
62–year–old female and were cultured and maintained in RPMI–1640 medium supplemented 
with 2% (v/v) L–G, 10% (v/v) FBS and 1% (v/v) Sodium Pyruvate (GibcoTM by Thermo 
Fisher Scientific, Waltham, MA, USA). The epithelial PANC–1 cells originate from 
epithelioid carcinoma in the pancreatic duct in a 56–year –old Caucasian male and cultured 
and maintained in DMEM– High glucose supplemented with 10% (v/v) FBS (Sigma–Aldrich, 
Inc., St. Louis, MO, USA), 1% (v/v) L–G (Sigma–Aldrich, Inc., St. Louis, MO, USA); 1% 
(v/v) Na–P (GibcoTM by Thermo Fisher Scientific, Waltham, MA, USA). 
 
The cells were cultured in 75cm2 cell culturing flasks (T75 flasks, VWR International Ltd., 
Leicestershire, UK) with ventilated lids and placed in a humidified incubator with 5% CO2 at 
37˚C (Thermo Fisher Scientific, Waltham, MA, USA) unless otherwise stated. A sterile 
laminar flow bench with a high efficiency particulate air filter was used for all cell culturing.  
 
3.1.2 Cell passaging 
All cell lines were passaged 2–4 times a week in accordance with manufacturers 
recommendations. Cells were counted using a Bürker or a Fuchs–Rosenthal counting 
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chamber. For passaging all reagents were pre–heated to room temperature (RT). MOLM–13 
cells were passaged by centrifuging the cells at 400 G for 5 min, resuspending in fresh 
medium and supplementing with fresh medium to the desired cell concentration. The adherent 
pancreatic cell lines were passaged by enzymatic dissociation from the flask at approximately 
80% confluency incubating with trypsin solution after washing the cells with Phosphate 
Buffered Saline (PBS) until the cells were detached from the flask. The trypsin was 
neutralized with 6.5 times the trypsin volume of fresh medium, and the solution was 
centrifuged at 400 G for 5 min at RT before resuspending in fresh medium obtaining the 
desired cell density in a new cell culture flask.   
 
3.1.2 Cryopreservation and thawing of cells 
For cryopreservation the cells were counted and resuspended at the desired cell concentration 
(1.0×106 – 5.0×106 cells/mL) in 95% complete growth medium and 5% Dimethyl sulfoxide 
(DMSO). To prevent cell damage from freezing too fast the aliquots were placed in a freezing 
container (Nalgene® Mr. Frosty) over–night at -80oC, which allows the cells to decrease in 
temperature by 1oC/hour protecting the cells. After 24h the cells were placed in -80oC freezer 
for long term storage. For thawing, the cells were thawed under running water at RT and pre–
heated medium was added within 10 min of retrieval from -80oC storage. The cells were 
centrifuged 400 G for 5 min at RT to remove the freezing medium containing cytotoxic 
DMSO. Then, the cells were resuspended in fresh medium and incubated as previously 
described. For the adherent cells each cell line was kept until a passage number of maximum 
20 passages, and a new batch of cells was started thereafter. The stock was obtained during 
the first few passages. 
 
3.2 Antibodies 
3.2.1 Positive controls and antibodies 
The antibodies (Table 7 – Appendix) corresponding to the proteins of interest for the 
pancreatic cell lines were tested prior to treating the cells with sonoporation to determine the 
presence and/or level of protein expression in the cell line. To induce phosphorylation or 
dephosphorylation different chemicals, referred to as positive controls (Table 9 – Appendix), 
known to induce phosphorylation or dephosphorylation, were used to stimulate the cells. 
These tests were used to test the antibodies and optimise the amount of protein extract 




3.3 Viability assays 
3.3.1. Trypan Blue apoptotic cell stain 
The nucleic acid trypan blue stain (0.4%, 1 µg/mL, 1:1 dilution; duplicates) was used for cell 
count following cell treatment, and to distinguish between dying/dead cells and viable cells. 
Only cells with a compromised plasma membrane take up the dye (63). The cells were 
counted using a Fuchs–Rosenthal counting chamber immediately after treatment (65).  
 
3.3.1.2 Hoechst 33342 apoptotic stain 
Hoechst 33342 is a fluorescent nucleic acid stain that will only stain dying and apoptotic cells 
with a compromised plasma membrane (64). Upon binding to A–T rich regions of dsDNA the 
Hoechst stain will undergo an approximately 30–fold increase in fluorescence. When exited 
by ultraviolet (UV) light (360 nm) the Hoechst stained cells will emit a blue fluorescence 
(460 nm) (65). The Hoechst solution was prepared (11.8 mL sterile PBS, 3.2 mL 37% 
formaldehyde and 0.03 mL (20 mM) Hoechst 33342 stock solution (10 mg/mL)) prior to 
treatment of cells. 100µL Hoechst solution was added to 100µl cell suspension (suspension 
cells) or cell culture media (adherent cells). (cell suspension: Hoechst is 1:1) (63). The plate 
was covered with Parafilm M, the lid and aluminium foil to preserve it, and stored at 4oC until 
imaging (64). Images were captured using a 5×/0.6NA 20× objective coupled to an inverted 
Axiovert microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany) using Zen Pro 
software (Carl Zeiss Microscopy GmbH, Göttingen, Germany). Image exposure time was set 
to 33 ms, and the light source (DAPI) was set to max. The images were analysed in Fijii 
software (ImageJ) number of Hoechst 33342 stained apoptotic cells and total number of cells 
were counted, and the percentage of apoptotic cells calculated.  and figures made in Graph 
Pad Prism (GraphPad Software, La Jolla, CA, USA). 
 
3.3.1.3 WST–1 metabolic assay 
The WST–1 assay (Roche, Ltd., Basel, Switzerland) provides an estimation of the amount of 
metabolically active cells in the sample. WST–1 is a tetrazolium salt that is cleaved to a 
soluble formazan. This reaction is dependent on nicotinamide adenine dinucleotide phosphate 
(NAD(P)H) in viable cells, and the amount of formazan dye formed directly correlates to the 
number of metabolically active cells. The method is sensitive detecting low cell numbers with 
longer incubation times (66). When light passes through the sample the density of the 
solute/colour determines how much light passes through. A sample of low density, such as a 
sample with few cells, or many apoptotic cells (not metabolically active), will have a low 
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absorbance, meaning little light has been absorbed by the sample. In a sample of high density 
with many metabolically active (live) cells less light will pass through the sample and more 
will be absorbed, meaning the sample will have a high absorbance. It is recommended to 
incubate the cells with the WST–1 reagent 0.5 – 4.0 hours, and optimisation for each cell line 
is recommended by manufacturer (67). The absorbance was measured using a plate reader 
(Spectra Max Plus 384) at 450 nm and 620 nm. The results were analysed in Microsoft Excel 
(Microsoft Office 2018) and figures made in Graph Pad Prism (GraphPad Software, La Jolla, 
CA, USA). The metabolic activity can be calculated by applying the following equation:   
 
%	𝑀𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑐	𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
= (𝑆𝑎𝑚𝑝𝑙𝑒	𝐴𝑏𝑠. 𝑎𝑡	450	𝑛𝑚 − 𝑆𝑎𝑚𝑝𝑙𝑒	𝐴𝑏𝑠. 𝑎𝑡	620	𝑛𝑚)
− (𝐵𝑙𝑎𝑛𝑘	𝐴𝑏𝑠. 𝑎𝑡	450	𝑛𝑚 − 𝐵𝑙𝑎𝑛𝑘	𝐴𝑏𝑠	𝑎𝑡	620	𝑛𝑚) 
 
3.3.2 Viability optimisation MOLM-13 
3.3.2.1 Hoechst 33342 
To reduce work and ensure more high-throughput analysis of dead cells following 
Hoechst staining, a new semi-manual method of counting dead cells was tested. This whole 
process was performed by two individuals to identify irregularities in the process. Following 
sonoporation (chapter 3.5.3) the Hoechst assay was performed according to protocol 
(chapter 3.3.1.2). Three images per replicate were then uploaded to Fijii software (ImageJ) 
and analysed separately. 
Count of total number of cells: 
• Image uploaded 
• Image converted to 16-bit 
• Brightness/contrast and threshold adjusted  
• Cells were counted by the software.  
Count of dead cells: 
• Image uploaded again 







To optimise incubation–time following sonoporation and the optimal cell concentration to 
seed a test was performed. 100 µl of untreated MOLM–13 cell suspension of different 
concentrations (0.05×106, 0.1×106, 0.2×106, 0.4×106, 0.8×106, 1×106) were seeded 
(triplicates) in a 96–well plate. 100 µl RPMI was used as a control. The cells were incubated 
for 24h Then, 10 µl WST–1 reagent was added to each well and the plate was incubated for 
0.5 h, 1h, 2h and 4h. The absorbance was read on a plate reader (Spectra Max Plus 384) at 
450 nm and 620 nm. The results were analysed as described in chapter 3.3.1.3. 
 
3.3.3 Viability optimisation MIA PaCa-2 
3.3.3.1 WST-1 - Cell number and incubation time for MIA PaCa-2  
In order to determine the optimal number of cells to seed, and the optimal incubation time for 
WST–1 assay following US treatment of MIA PaCa–2 cells a test was performed. 1×106 MIA 
PaCa–2 cells (maintained in DMEM) were seeded in Petakas and incubated for 24h Then, the 
cells were sonoporated at 358 mW/cm2 for 5 min and incubated for 60 min. The cells were 
detached with pre-heated 1× trypsin as describer previously. Then, 0.1×104, 0.2×104, 
0.4×104, 0.8×104, 1.6×104, 3.2×104 and 6.4×104 cells were seeded (duplicates) in a 96–well 
plate. The cells were incubated further 24h before adding 10 µl WST–1 reagent. Absorption 
was read with an ELISA plate reader (Spectra Max Plus 384) at 450 nm and 620 nm after 1h, 
2h and 4h incubation. The results were analysed as described in chapter 3.3.1.3. 
 
3.3.3.2 Viability test of MIA PaCa-2 in Petakas 
To assess the optimal seeding density for viability assays for MIA PaCa–2, cells cultured in 
Petakas, were either serum-starved or (cultured in DMEM without any additives) or treated 
with high US (Table 3) and Sonazoid MBs (5.6 µL/mL). Cell not treated were the control. 
After 60 min. of incubation following sonoporation, cells from each sample (High US, 
Serum–Starved, Control) were seeded for Trypan blue counting, Hoechst 33342 and WST-1 
assays.  
 
• Trypan Blue 
MIA PaCa-2 cells were stained with a 0.4% solution of trypan blue (1:1 dilution; 
duplicates).  Stained and unstained cells were counted immediately following treatment 





• Hoechst 33342 
32×104 cells were seeded (triplicates) from each sample (High US, Serum-Starved, 
Control) and incubated for 24h before adding 100 µl Hoechst 33342 solution. The plate 
was preserved and imaged as described previously (chapter 3.3.1.2). The Hoechst 
seeding test was repeated seeding 0.8×104 and 1.6×104 (triplicates) with untreated MIA 
PaCa–2 cells, which was assessed visually. 
 
• WST-1 
32×104  cells were seeded (triplicates) from each sample (High US, Serum-Starved, 
Control) and incubated for 24h. before adding 10µl Cell Proliferation Reagent WST-1 
/well. The plate was incubated for 2h before reading the absorbance on a plate reader 
(Spectra Max Plus 384) at 450 nm and 620 nm. The results were analysed as described in 
chapter 3.3.1.3. 
 
3.5 Ultrasound treatment of cells in vitro 
3.5.1 MOLM–13  
The custom–made suspension cell plate sonicator used in this project is made for regular 24–
well plates (68) (Figure 10A–B). The device has six US transducers focused in the middle of 
each well. The six wells allow for testing different treatments simultaneously, for example 
MBs or drugs. The plate sonicator is controlled by a custom program written in LabVIEW 
(National Instruments Corporation, Austin, TX, USA) with a user–friendly interphase (Figure 
10B). Prior to the experiment a file is written indicating the name, frequency, pressure, 
intensity, and duration required for each experiment. This file is read by the software and all 
parameters are automatically calculated (68) . 
 
Figure 10: Computer generated renderings of the custom–made suspension cell plate sonicator for 24–
well plates. Cutway diagram showing assembly (A) Figure from (68). Top view showing position of 




3.5.2 Cell culture before experiments 
MOLM–13 cells were cultured and seeded at 0.5×106 cells/mL until they experienced log–
phase growth. Then, 2.5 mL 0.4×106 cells/mL MOLM–13 cell suspension (maintained in 
RPMI–1640) was seeded per well (1×106 cells/well) in 6 wells, corresponding to the US 
transducers of the plate sonicator, and kept stored in the incubator for 1–2h until sonoporation 
(69). 
 
3.5.3 Ultrasound and microbubble treatment 
MOLM–13 cells were treated with three different US conditions (Table 1). The US intensities 
used in the studies of MOLM–13 were 74 mW/cm2, 501 mW/cm2 and 2079 mW/cm2, later 
referred to as Low, Medium and High (Table 1). Before US treatment the plate covered with 
a self–adhering thin membrane (TopSeal ™ –A; Perkin Elmer, Waltham, MA, USA), 
measured to have < 1% pressure attenuation at 1 MHz, and was placed inverted in the water 
bath. The TopSeal™ has been measured to have < 1% pressure attenuation at 1 MHz (70). 
 









Control 0 0 0 0 0 
Low 74 0.2 4 1.108 10 
Medium 501 0.3 16 1.108 10 
High 2079 0.4 37 1.108 10 
 
MOLM–13 cells were treated with and without MBs at Low, Medium and High US intensity 
(Table 1) for 10 min. Following US treatment cells were harvested for viability assays. The 
trypan blue assay was performed within 5 min of sonoporation, while cells for Hoechst 33342 
were incubated for 24h before fixing the cells. Protein extraction was performed within 5 min 
and after 2h incubation following sonoporation. The procedure for cells treated with MBs 
extracting proteins within 5 min of sonoporation is described below. Before MB addition 
Sonazoid MBs were prepared according to manufacturer’s recommendations; the MBs were 
resuspended in 2 mL sterile NaCl (0.9%) and diluted 1:10 before addition to the cells (cells : 
MBs are 1:1). MBs were added immediately before sonoporation. Cells not treated with US 
were used as control. After sonoporation cells from 6 wells were collected. Then, cells were 
seeded for viability assays and cells were prepared for protein extraction within 5 min 
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following sonoporation. Protein was extracted as per protein extraction protocol and prepared 
for WB (chapter 3.7).   
 
3.5.4 MIA PaCa–2 
The custom–made adherent cell plate sonicator has a water bath that sits on the electronics 
case containing a 128–element array (90 cm2 treatment area) of US transducers. The carriage 
has a removable acoustic absorber, the Aptflex F28, which is placed above the Petaka 
absorbing the US, thereby, minimises standing waves. The Petaka is placed in the carriage 
with the upper surface facing down (68) (Figure 11). 
Figure 11: Computer generated rendering of the custom–made adherent cell plate sonicator. Cutway 
diagram showing assembly. The Petaka is placed in the carriage containing the acoustic absorber 
before it is positioned in the water bath. The sonicator contains a 128–element array of ultrasound 
transducers covering the whole cell culture surface of the Petaka. 
 
 
The plate sonicator is controlled by a custom program, based on the program for the 24–well 
plate sonicator, written in LabVIEW, with a user–friendly interphase. Prior to the experiment 
a file is written indicating the name, frequency, pressure, intensity, and duration required for 
each experiment. This file is read by the software and all parameters are automatically 
calculated (68). 
 
3.5.5 Cell culture before experiments 
MIA PaCa-2 cells were cultured at a density between 2×106 and 7×106 cells in T75 flasks 




3.5.6 Protocol for seeding adherent cells in Petaka 
The cells were detached by pre-heated 1× trypsin. Trypsin was neutralized with medium and 
the cell suspension was centrifuged at centrifuged at 400 G for 5 min. Cells were then counted 
and resuspended. Then, 3×106 cells in 26 mL medium (1.15×105 cells/mL) were injected into 
the Petaka. Air pockets were removed before sealing the ventilation port with adhesive tape to 
avoid new air leaking into the Petaka during incubation and handling. The Petaka was 
incubated for 24h in a horizontal position to allow the cells to adhere. After 24h the Petaka 
was placed in a vertical position. The Petaka was then incubated further 24–36 h to achieve 
log–phase growth and to ensure there is enough cells for WB analysis.  
 
3.5.7 Protocol for detachment of adherent cells in Petaka 
To detach the cells from the Petaka the ventilation port seal was removed, and the supernatant 
aspirated. Then, to wash residual medium and debris 10 mL ice–cold PBS was injected with a 
30mL syringe and the Petaka swirled to cover all cells. The PBS was aspirated before 
injecting 3 mL ice–cold trypsin, swirling the Petaka to cover all cells, and incubating on ice 
for ~30 min to detach the cells. Next, the trypsin was neutralized by injecting 10 mL ice–cold 
DMEM with a 30mL syringe, swirling the Petaka. The supernatant was then transferred to a 
50mL tube and centrifuged at 400 G for 5 min at 4oC. Protein was extracted as per protein 
extraction protocol and prepared for WB (chapter 3.7) 
 
3.6 In vitro optimisation  
3.6.1 Optimisation of cell lysis 
To be able to plan how many WBs could be performed from one experiment using Petakas 
the protein concentration from 1×106 MIA PaCa–2 cells were quantified. The cells were 
harvested when passaging cells, counted and quantified using DC™ Protein Assay Kit as per 
protein quantification protocol (chapter 3.7.2). 
 
3.6.2 Optimisation of growth rate for MIA PaCa–2 in Petaka 
In order to ensure optimal conditions for cell growth in the Petaka MIA PaCa–2 cells, 
cultured in Petakas, compared to MIA PaCa–2 cells grown in T75 flasks, was investigated. 
The objective was to ascertain the cells growth rate to identify at which time–point the cells 
were in log phase, and to identify when the cell growth plateaus. The growth rate was 
determined by the mean of mean cell count per surface area. 
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MIA PaCa–2 cells (1×106/26 mL), were seeded in two Petakas, and one T75 culturing flask, 
and incubated for 48 h. The Petakas and the T75 flasks were cultured for further 5 days and 
monitored daily using a Leika microscope. The cells were imaged approximately every 24h 
for 5 days, the first images taken 24h after seeding. Images were captured using a 5×/0.6NA 
20× objective coupled to an inverted Axiovert microscope (Carl Zeiss Microscopy GmbH, 
Göttingen, Germany). Image exposure time was set to 6.5 ms, and the light source was set to 
max. The images were saved in 16bit czi format. A total of 50 images per Petaka were 
captured. MIPAR batch processor (MIPAR, Worthington, OH, USA) was used measure the 
surface area occupied by the MIA–PaCa–2 cells. The exact recipe settings can be seen in the 
appendix (Table 10). Figure 12 shows a general overview of the process with the major 
steps. 
Figure 12: Overview protocol of Hoechst Imaging analysis. Images captured using a 5×/0.6NA 20× 
objective coupled to an inverted Axiovert microscope (Carl Zeiss Microscopy GmbH, Göttingen, 
Germany; image exposure time; 6.5 ms. Light source; max.16bit image czi format). 50 images 
captured per Petaka. MIPAR batch processor (MIPAR, Worthington, OH, USA) was used measure the 
surface area occupied by the MIA PaCa–2 cells. The contrast was adjusted, and the background was 
flattened to correct for illumination inhomogeneity. A dark texture filter was used to highlight dark 
components of the image via a grayscale closing method. A standard deviation filter was used to 
accentuate the cell edges by brightening pixels which have dissimilar neighbours. A range threshold 
was applied, holes were filled, and areas of 800 pixels or less were rejected to remove false positives. 
The percentage of selected pixels as a ratio of the original image size was considered the percentage 
surface area covered by cells. 
 
3.6.3 Optimisation of cell detachment  
3.6.3.1 Optimisation of timing of cell detachment with cold 1× trypsin and 10× trypsin 
The objective was to determine how long it would take to detach untreated MIA PaCa–2, 
PANC–1 and BxPC–3 cells with ice–cold 1× trypsin and 10× trypsin 3×106 cells of each cell 
line were seeded in two T75 flasks per cell line and incubated for 48 h. The cells were washed 
once with ice–cold sterile PBS, then, ice–cold 1× trypsin or 10× trypsin was added, and the 
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flask put on ice. The flasks were monitored by microscope until the cells were detached and 
the time it took for the cells to detach was noted.  
 
3.6.3.2 Optimisation of cell detachment–western blot 
Since trypsin may affect cell signalling results (59, 60), the possible influence of cell 
detachment with 1× trypsin was investigated. Three methods of cell detachment were tested, 
trypsin– 4oC (1), trypsin RT (2) and scraping (3). Cell detachment by scraping in a Petaka is 
possible using a magnet (62), however, due to the lack of necessary equipment to accomplish 
this, enzymatic cell detachment was used in this project. For this test 3×106 MIA PaCa–2 
cells, (maintained in DMEM,) were seeded in six T75 flasks and incubated for 48 h. For each 
detachment method one flask of cells was stimulated with A23187 (1µM) + PMA (0.1µM)  
for 30 min to investigate influence on phosphorylation. Untreated cells were used as controls.  
 
Detachment following stimulation: 
1. Trypsin 4oC:  
o Cells were washed twice with ice–cold PBS.  
o 1× trypsin was added, and the cells were kept on ice until the cell detached 
from the flask.  
o After the cells were detached the trypsin was neutralized with ice–cold 
DMEM.  
 
2. Trypsin 37oC:  
o Cells were washed twice with PBS (37oC). 
o 1× trypsin (37oC) was added and the cells were kept in the incubator until the 
cell detached from the flask. 





o cells were washed twice with ice–cold PBS. 
o 1 mL RIPA lysis buffer was added and the flask swirled to cover the cells, then 




Protein was extracted from all samples as per protein extraction protocol and prepared for WB 
(chapter 3.7). 30 µg protein was loaded in the gel from each sample.  
 
3.6.3.3 Optimisation of cell detachment with 10× trypsin –Viability and western blot 
In order to determine whether 10× trypsin affects cell signalling a test was performed with 
the MIA PaCa–2, PANC–1 and BxPC–3 cell lines. 3×106 cell of each cell line was seeded in 
two T75 flasks per cell line and incubated for 48 h. For each cell line one flask of cells was 
stimulated with A23187 (1µM) + PMA (0.1µM) for 30 min Untreated cells were used as 
controls. The viability assay Trypan blue, WST–1 and Hoechst 33342 was used to assess how 
10× trypsin affected the cells viability. Following stimulation cells were detached with cold 
trypsin as described in chapter 3.6.3.2 and viability assays performed is previously described 
(chapter 3.3.1.1–3.3.1.3). WST-1 32×104 cells, Hoechst 33342 1.6×104 cells. After viability 
assays were seeded protein was extracted as per protein extraction protocol and prepared for 
WB (chapter 3.7). 
 
3.6.4 Optimisation of incubation time following sonoporation 
MIA PaCa–2 cells were sonoporated with Sonazoid MBs and cells were harvested after 5 
min, 1h, 2h, and 4h incubation in Petakas to investigate phosphorylation kinetics. Five 
Petakas were seeded with 3×106 MIA PaCa–2 cells (maintained in DMEM) and incubated for 
48 h as previously described (chapter3.5.6). Then, the cells were sonoporated at 358 
mW/cm2 (referred to as High US) for 5 min One Petaka was not sonoporated (control), the 
second was lysed 5 min after sonoporation, the third Petaka after 1h, the fourth after 2., and 
the fifth after 4h incubation. Protein was extracted as per protein extraction protocol and 
prepared for WB (chapter 3.7). 
 
3.6.5. Optimisation of western blot 
To be able to determine the approximate protein level expressed of each protein investigated, 
optimisation of each Ab corresponding to the protein of interest was performed. These tests 
were also used to check that antibodies and recommended antibody concentrations worked as 
expected/intended. MIA PaCa–2 cells were stimulated with drugs of relevant targets (Table 
2), known to induce phosphorylation of the proteins in question. For each test 3×106 MIA 
PaCa–2 cells (maintained in DMEM) were seeded in T75 culturing flasks and 
treated/stimulated after 48 h incubation with their respective stimuli for different time–periods 
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(Table 2). Protein was extracted as per protein extraction protocol and prepared for WB 
(chapter 3.7), and 30 µg, 40 µg and 50 µg protein were loaded per well. 
 
Table 2: Positive controls – Induction of phosphorylation 
Antibody/Epitope Stimuli 
ERK 1/2 (Thr202/Tyr204) *TNFα 15 min 






p–eIF2α (Ser51) A23187 4h 
MYPT1 (Ser 853) 
MYPT1 (Ser 696) 
*TNFα = Tumour necrosis factor 
**PMA = Phorbol 12–myristate 13–acetate 
 
3.6.6 Ultrasound and microbubble treatment of MIA PaCa–2 
MIA PaCa–2 cells were treated with three different US conditions (Table 3) in the custom-
made adherent cell plate sonicator (Figure 10). The US intensities used in the studies of MIA 
PaCa–2 are referred to as Low, Medium and High and refers to 3 mW/cm2, 50 mW/cm2 and 
358 mW/cm2 respectively (Table 3).  
 









Control 0 0 0 0 0 
Low 3 0.1 20 2.0 5 
Medium 50 0.2 80 2.0 5 
High 358 0.378 160 2.0 5 
 
The MIA PaCa–2 cells were treated with 5.6 µL/mL Sonazoid MBs. The concentration of 
microbubbles was based on a–priori knowledge. Four Petakas were seeded with 3×106 MIA 
PaCa–2 cells (maintained in DMEM), cultured and detached as described in chapters 3.5.5 – 
3.5.7. Sonazoid MBs were prepared according to manufacturer’s recommendations; the MBs 
were resuspended in 2 mL sterile NaCl (0.9%) and diluted 1:10 before immediately before 
injecting 1 mL MB–suspension (4.8×106 ppmL) into the Petaka (cells:MBs are 1:1). The 
experiment was repeated in full for the samples not treated with MBs. Here, NaCl only was 
Silje	Maria	Sundøy	 	 University	of	Bergen	
	 42	
injected instead of a NaCl-MB suspension to mimic the treatment with MBs. Cells treated 
with MBs that were not treated with US was used as control, however, the cells were left for 5 
min in the sonicator in order to treat the samples as equal as possible. The Petakas were 
injected with MBs immediately before sonoporation. Cells were sonoporated for 5 min at 
Low, Medium or High US intensity (Table 3) and then incubated for 2h. The cells were 
imaged immediately after sonoporation and then incubated for 2h. In experiments where 
microbubbles were added the cells were imaged immediately after sonoporation. After 
incubation for 2hours, the cells were detached by cold–trypsinization (1×  trypsin) as 
described earlier. The trypsin was neutralized with ice–cold DMEM, the cell suspension 
resuspended, and cells were extracted for trypan blue counting. Then, the samples were 
centrifuged at 400 G for 5 min (4oC), resuspended in cold DMEM and diluted to 32×104 
cells/µl and 1.6×104 cells/µl for WST–1 and Hoechst assays, respectively. 100 µl of each 
sample (Ctr., Low US, Medium US, High US) was seeded (triplicates) in a 96–well plate and 
incubated for 24h. After seeding for viability assays the samples were prepared for protein 
extraction for WB analysis as described earlier. After 24h viability assays were performed as 
described earlier (chapter 3.3.1.1–3.3.1.3).  
 
3.7 Western blot 
3.7.1 Protein extraction  
Following treatment all cell lines were subject to the same extraction procedure. Samples 
were kept on ice between centrifugation steps. The cell suspension of each sample was 
centrifuged at 400 G for 5 min, supernatant aspirated and the cells washed with 10 mL cold 
PBS and again centrifuged at 400 G for 5 min Then, the supernatant was removed, and the 
pellet resuspended in 1 mL cold PBS in an Eppendorf tube and centrifuged at 400 G for 5 min 
Next, the supernatant was carefully removed by micropipette and the pellet was dissolved in 
RIPA lysis buffer supplemented with 1:100 HaltTM Protease & Phosphatase Inhibitor Cocktail 
and 1:100 0.5 M EDTA solution. To ensure that the pellet would dissolve and get a 
homogenous cell lysate, the pellet was dissolved by mechanical homogenization (repeated 
pipetting in RIPA buffer). For protein extraction 100 µl RIPA /1×106 cells, and 50 µl RIPA/ 
1×106 cells were used for MOLM–13 and MIA PaCa–2 cells, respectively. The lysates were 
immediately incubated on ice and left for 15 min before centrifuging at 14000 G for 15 min 




3.7.2 Protein quantification and sample preparation 
The protein concentration was quantified using the colorimetric DC™ Protein Assay Kit 
(Bio–Rad Laboratories, Hercules, CA, USA(71)) with a serial dilution working range of 0.0 
µg/mL – 2000 µg/mL. First, 5 µl of protein extract was added to a 96–well plate (triplicate). 
Then, 25 µl of working reagent A’ (2% (v/v) of reagent S mixed with reagent A) and 200µl 
reagent B was added. All extracts were measure in triplicates to ensure precision. The plate 
was incubated in RT for 15 min before determining the protein concentration by reading the 
absorbance on an ELISA plate reader (Spectra Max Plus 384) at 720 nm. The protein extracts 
were denatured at 100oC for 5 min in 1× Loading buffer (200mM Tris–HCl (pH 6.8), 400 
mM DTT, 8% SDS, 0.4% bromophenol blue, 40% glycerol), then cooled on ice for 10 min 
before loading the samples in the gel.  
 
3.7.3 Sample reparation MOLM–13 
For WBs with MOLM–13 26 µg protein extract was loaded in the gel.  
 
3.7.4 Sample preparation pancreatic cell lines 
For WBs with pancreatic cell lines (MIA PaCa–2, PANC–1, BxPC–3) 30–50 µg protein 
extract was loaded in the gel depending on the cell line and protein concentration of the cell 
lysate.  
 
3.7.5 Gel electrophoresis 
The protein extracts were separated by size using 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis system (SDS–PAGE; Mini–PROTEAN Tetra 
Electrophoresis System; Bio–Rad Laboratories, Hercules, CA, USA), according to 
manufacturer’s protocol. SDS is a strong anionic detergent added to coat hydrophobic regions 
of proteins with negative charge, thus overpowering positive charges in proteins (1). By 
adding SDS in the loading buffer, gel and buffers denaturing of the proteins is ensured and 
gives the protein lysate a uniformly distributed negative charge.  
When exposed to an electrical current the proteins will migrate towards the positive electrode 
(anode) and be separated in the gel by size. The gel was hand–cast using the Mini–
PROTEAN® tetra hand–caste system with 1.0 and 1.5 mm Spacer Plate and Short Plate (Bio–
Rad Laboratories, Hercules, CA, USA). ~ 7.5 mL resolving gel (25% (v/v) 1.5 M Tris–HCl 
(pH 8.8), 1% (w/v) SDS, 1% (w/v) ammonium persulfate (APS; Bio–Rad Laboratories, 
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Hercules, CA, USA), 0.06% (v/v) TEMED (Bio–Rad Laboratories, Hercules, CA, USA) and 
27% (v/v) 30% Acrylamide/Bis solution.) was added to the cast. 500µL ultrapure water (MQ–
H2O; processed by Milli–Q® Type1 Ultrapure Water System; Merck Millipore, Billerica, 
MA, USA) was carefully added on top of the gel to ensure a flat surface. The gel was left to 
solidify for ~ 1h. Then, the MQ–H2O was removed, and ~ 2.5 mL stacking gel (12.5% (v/v) 1 
M Tris–HCl (pH 6.8), 1% (w/v) SDS, 1% (w/v) APS, 0.1% (v/v) TEMED and 6.5% (v/v) 
30% Polyacrylamide/Bis solution) was added on top of the resolving gel. A 1.0 mm/10welled 
or 1.5mm/15 welled comb (Bio–Rad Laboratories, Hercules, CA, USA) was immediately 
inserted in the cast and left to solidify for ~15 min Next, the gel was placed in the Mini–
PROTEAN® electrophoresis system (Bio–Rad Laboratories, Hercules, CA, USA). Running 
buffer 0.3% (w/v) Tris Salt, 1.5 (w/v) Glycine and 0.1% (w/v) SDS was added to the marked 
level and the combs were removed submerged in buffer. 3–5 µL Precision Plus ProteinTM All 
Blue Standards (Bio–Rad laboratories, Hercules, CA, USA) was added to the first and last 
well to help identify the separated proteins. 
 
3.7.8 Electrophoretic transfer of proteins 
The separated proteins were transferred from the gel to a nitrocellulose membrane (Bio–Rad 
Laboratories, Hercules, CA, USA) using a wet transfer (Mini Trans–Blot® Cell; Bio–Rad 
Laboratories, Hercules, CA, USA). The transfer buffer (0.3 (w/v) Tris Salt and 1.5% (w/v) 
Glycine) was prepared in advance and cooled to 4oC. For one gel two pieces of extra thick 
blot paper (Bio–Rad Laboratories, Hercules, CA, USA), two black sponges and the membrane 
was soaked in transfer buffer for ~ 10 min Then the gel holder cassette was assembled 
carefully as follows: a sponge, a blot paper, the gel, nitrocellulose membrane, a blot paper and 
finally a sponge. All the parts were kept wet and assembled to avoid air pockets between the 
gel and the nitrocellulose membrane. Next, the gel holder cassette was placed in the electrode 
module with the gel facing the negative electrode (cathode), which was inserted in the buffer 
tank with a frozen cooling unit to avoid the transfer to overheat and deregulate the proteins. 
The buffer tank was placed in a bucket of ice to aid with the cooling of the transfer. Transfer 
buffer was filled to the designated mark. The proteins were transferred at 240 Ampere for 150 
min After transfer the membrane was washed in MQ–H2O, then soaked in Ponceau red 
solution for ~ 1 min to confirm the loading consistency of protein samples. An image was 





After staining with Ponceau red the membrane was incubated in 10 mL blocking buffer (5% 
(w/v) non–fat milk solution (Skim Milk Powder; Sigma–Aldrich, Inc., St. Louis, MO, USA) 
in 1× Tris Buffered Saline (TBS) supplemented with and 0.1% (v/v) Tween® 20 (Sigma–
Aldrich, Inc., St. Louis MO, USA) for 1hour in RT. Subsequently, the membrane was 
incubated with the respective primary antibodies corresponding to the assayed proteins 
(Table 7 – Appendix) over–night at 4oC. The antibodies were diluted according to the 
manufacturer’s recommendations (Table 7 – Appendix) in blocking buffer. COX IV mAb 
was used as a loading control (Table 7 – Appendix). After over–night incubation with 
primary Ab the membrane was washed with MQ–H2O thrice and incubated in blocking buffer 
for 10 min in RT. This washing step was repeated twice before incubating the membrane with 
rabbit or mouse secondary peroxidase Ab corresponding to the species of the primary Ab 
target (Table 8 – Appendix) for 1h. Then, the membrane was again washed thrice in MQ–
H2O and blocking buffer and placed in 1× TBS and imaged as soon as possible. The protein 
bands were visualized by incubating the membrane in 3 – 4 mL SuperSignalTM ELISA Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA), or 2 – 3 mL 
SuperSignalTM West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, 
Waltham, MA, USA) for the Ab with weaker signal. Imaging (and analysis) was performed 




The results are expressed as mean values ± SD, unless otherwise indicated.  
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4.0 Results 
4.1 Results MOLM–13 
4.1.1 Optimisation of WST–1 for MOLM–13 
A pilot study was performed to determine which cell concentration to seed, and how long 
incubation–time following sonoporation was optimal for WST–1 metabolic assay for 
MOLM–13 cells (Figure 13). Untreated cells were seeded at concentrations between 0.5×106 
and 1.0×106 and incubated between 0.5 and 4h. The fluorescence absorbance increases with 
increasing number of viable cells, as expected. At 0.8×106 cells the reaction is saturated 
because the WST–1 reagent has been used up or metabolized.  
 
Figure 13: WST–1 based metabolic assay for MOLM–13. Metabolic activity evaluated in untreated 
MOLM–13 cells, seeded at concentrations between 0.5×106 and 1.0×106 and incubated between 0.5 
and 4h). The absorbance was read on an ELISA plate reader (Spectra Max Plus 384) at 450 nm and 




4.1.2 Viability – trypan blue and Hoechst staining of sonoporated MOLM–13 
MOLM–13 cells (0.4×106/mL) were sonoporated with or without Sonazoid MBs (cells:MBs 
were 1:1) at Low US (74 mW/cm2), Medium US (501 mW/cm2) or High US (2079 mW/cm2) 
for 10 min (control was not sonoporated) as described in chapter 3.5.3. Viability assays were 
performed as per chapter 3.3.1 (trypan blue) and 3.3.2.1 (Hoechst 33342). 5 min after 
sonoporation there was no change in cell concentration in both the samples with and without 
MBs, compared to the control, and no significant cell death was observed. Some cell uptake 
of trypan blue was observed in samples treated with MBs at 0h with increasing US intensity 
(Figure 14A+B). After 24h cells in all samples not treated with MBs had proliferated 
(measured as increase in cell concentration) with little cell death observed (Figure 14C). 
However, in the samples treated with MBs the samples with Medium and High US intensity 
showed a trend of decreasing proliferation ability and increasing cell death, compared to the 
control, after 24h (Figure 14D). Of the Hoechst stained cells there was no difference in 
percent apoptotic cells between the samples, compared to the control without MBs. However, 
with MBs added there is a clear trend of increasing percent apoptotic cells with increasing US 





Figure 14: Trypan blue (proliferation) and Hoechst 33342 (apoptosis) assessment of sonoporated 
MOLM–13 cells. Cells were sonoporated with (+) or without (–) Sonazoid microbubbles (MBs, 
cells:MBs were 1:1) at Low (74 mW/cm2), Medium (501 mW/cm2) or High (2079 mW/cm2) 
ultrasound (US). Control was not sonoporated. Trypan blue stained cells (1:1 dilution) were counted 
after 5 min and after 24h incubation (5% CO2, 37˚C). After 5 min there was no change in cell count 
+/– MBs, compared to the control (A+B). After 24h all samples –MBs had proliferated (C). However, 
after 24h Medium and High US intensity +MBs had a decrease in proliferation, and increase in cell 
death, compared to the control (D). Hoechst stained cells –MBs revealed no difference in percent 
apoptotic cells between the samples, compared to the control (E). However, +MBs had increasing 
percent apoptotic cells with increasing US intensity (F). 
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4.1.3 Western Blot analysis MOLM–13 
MOLM–13 cells (0.4×106/mL) were sonoporated with or without Sonazoid MBs (cells:MBs 
were 1:1) at Low US (74 mW/cm2), Medium US (501 mW/cm2) or High US (2079 mW/cm2) 
for 10 min. Control cells were not sonoporated but treated with MBs (Figure 14). Cell lysates 
were analysed by WB to evaluate the relative protein expression using 26.7 µg protein/well. 
p38 was increasingly phosphorylated with increasing US intensity in samples with MBs 
harvested 5 min post sonoporation and in the control (Ctr.) and high US intensity (2079 
mW/cm2). 2h post sonoporation p38 had an increase in phosphorylation in samples with MBs 
only. Phosphorylation of ERK 1/2 was increased both with and without MBs 5 min post US, 
but a lower phosphorylation after 2h incubation (Figure 15). No phosphorylation of eIF2α 
was seen 5 min post sonoporation but increasing phosphorylation with increasing US intensity 
after 2h with MBs was observed. S6 was phosphorylated in all samples. STAT3 (Tyr705) was 
not phosphorylated 5 min post sonoporation, however, some phosphorylation in the Ctr. and 
Low US intensity (74 mW/cm2) 2h post sonoporation. STAT3 (Ser727), however, was 
phosphorylated in all samples. SAPK/JNK was not phosphorylated after 5 min but JNK was 




Figure 15: Western blot of sonoporated MOLM–13 cells. MOLM–13 cells (0.4×106/mL) were 
sonoporated with or without Sonazoid microbubbles (cells:MBs were 1:1) at Low ultrasound (US; 
74mW/cm2), Medium US (501mW/cm2) or High US (2079mW/cm2) for 10 min Control was not 
sonoporated. Cell lysates were analysed by western blot to evaluate the relative protein expression 
using 30.0 µg protein/well. p38 was increasingly phosphorylated with increasing US intensity in 
samples with MBs harvested 5 min post sonoporation and in the control (Ctr.) and high US intensity 
(2079 mW/cm2). 2h post sonoporation p38 had an increase in phosphorylation in samples with MBs 
only. ERK 1/2had increasing phosphorylation with and without MBs 5 min post sonoporation but had 
a weaker signal after 2h incubation. SAPK/JNK was only phosphorylated after 2h. eIF2α was not 
phosphorylated 5 min post sonoporation but were increasingly phosphorylated with increasing US 
intensity after 2h with MBs. S6 was phosphorylated in all samples. STAT3 (Tyr705) was not 
phosphorylated 5 min post sonoporation, however, weakly phosphorylated Ctr. and Low US intensity 
(74 mW/cm2) 2h post sonoporation. STAT3 (Ser727), however, was phosphorylated in all samples.  
 
4.2 Results Pancreatic cell lines 
4.2.1 Optimisation of cell lysis 
To be able to plan how many WBs could be performed from one experiment using Petakas 
the protein lysates from 1×106 MIA PaCa–2, PANC–1 and BxPC–3 cells using 50 µl RIPA 
buffer according to WB protocol (chapter 3.7) and quantified using DC™ Protein Assay Kit 
as per protein quantification protocol (chapter 3.8.0). MIA PaCa–2 (n=3) and PANC–1 (n=3) 
had a mean protein concentration of 2.774 µg/µl and 3.495 µg/µl, respectively. BxPC–3 had a 
protein concentration of 2.208 µg/µl (n=1) (Table 4). This resulted in 4, 5 and 3 WBs for 
MIA PaCa–2, PANC–1 and BxPC–3, respectively, using 30 µg/well. When using 40 µg/well 




Table 4: Quantification of 1×106 cells lysed in 50 µl RIPA buffer 
Cell line Protein 
concentration. 
(µg/µl) 
# of western blots with  
30 µg/well 
# of western blots with  
40 µg/well 
MIA PaCa–2 (n=3) 2.774 4 3 
PANC–1 (n=3) 3.495 5 4 
BxPC–3 (n=1) 2.208 3 2 
 
4.2.2 Viability optimisation MIA PaCa-2 
4.2.2.1 WST-1 - Cell number and incubation time for MIA PaCa-2 
In order to determine the optimal number of cells to seed, and the optimal incubation time for 
WST–1 assay following US treatment of MIA PaCa–2 cells a test was performed (Figure 16). 
The absorption increased with increasing cell number seeded, as expected. The cells 
incubated for 1h peaked at 1.6×104 cells seeded and then the curve plateaued. Cells incubated 
for 2hours had a steady increase in absorbance with increasing cell number seeded and at 
6.4×104 cells the absorbance increased markedly. The cells incubated for 4h increased 
steadily with increasing cell number seeded (Figure 16).  
 
 
Figure 16: Optimisation of cell number seeded and incubation time for WST–1 for MIA PaCa–2 in 
Petaka. Metabolic activity evaluated in sonoporated (358 mW/cm2 for 5 min) MIA PaCa–2, cultivated 
in Petakas, by WST–1–bases assay. Untreated cells were used as control. Different cell numbers 
(between 1×104  and 6.4×104; duplicates). Absorbance read 1h, 2h and 4h following sonoporation. 




4.2.2.2 Viability test of MIA PaCa-2 in Petakas 
To determine the optimal conditions for viability assays for MIA PaCa-2 cells treated with US 
in Petakas a test was performed. Treatment and procedure for viability assays (Trypan blue, 
Hoechst 33342 and WST-1) are described in chapter 3.3.3.2. The trypan blue resulted in no 
trypan blue stained cells (data not shown).  
A significant difference was found between the serum–starved cells and the control, and 
between the serum–starved cells and cells treated with High US (Figure 17B). The control 
and the cells treated with High US had a similar absorbance (Figure 17B).) The decreased 
metabolic activity seen in serum–starved cells, compared to the control, was expected. The 
cell density used for WST-1 (3.2×103 cells) was therefore used in further assays. For the 
Hoechst assay, the cells were too densely seeded for semi-automated counting. The software 
(Fijii) used to count the cells were unable to distinguish between single cells for the Control 
and cells treated with High US. The serum–starved cells, however, could be been quantified 
by this method (Figure 17B).  
 
Figure 17: Viability test for MIA PaCa–2. WST–1 analysis (A). Hoechst analysis (B). MIA PaCa–2 
were incubated (5% CO2, 37˚C) in Petakas for 24h Serum supplemented medium was replaced in one 
Petaka (Starved) with serum–free medium and all Petakas were incubated further 24h One Petaka was 
treated with ultrasound (US) at 358 mW/cm2 (High US). Untreated cells were kept as control 
(Control). 3.2×104  cells/100 µl/well were seeded (triplicates) in a 96–well plate for WST–1 and 
Hoechst and incubated for 24h 10 µl WST–1 reagent/well (1:10 dilution) was added and absorbance 
read after 2h on an ELISA plate reader (Spectra Max Plus 384) at 450 nm and 620 nm. (A). Cells were 
fixed with 100 µl Hoechst reagent/well. Images captured with an inverted Axiovert fluorescent 




The Hoechst test was repeated seeding 0.8×104 and 1.6×104  (triplicates) with untreated MIA 
PaCa–2 cells. The seeding density was evaluated by light microscopy and not by the software 
due to poor image quality. It was determined that 1.6×104 cells/well was satisfactory for 
further sonoporation studies (Figure 18).  
 
Figure 18: Hoechst seeding test. 100 µl untreated MIA PaCa–2 cells (0.8×104 cells/well and 1.6×104   
cells/well) were seeded (triplicates) in a 96–well plate and fixed with 100 µl Hoechst reagent (1:1 
dilution). Images captured with an inverted Axiovert fluorescent microscope (Carl Zeiss Microscopy 
GmbH, Göttingen, Germany). The seeding density at 1.6×104 cells/well, evaluated visually, was 
determined to be satisfactory for further studies with MIA PaCa–2.  
 
 
4.2.4 Optimisation of growth rate for MIA PaCa–2 in Petaka  
To determine the optimal seeding cell density and incubation time before cell treatment the 
growth rate of 1×106 MIA PaCa–2 cells seeded in Petakas, compared to 1×106 cells growth 
in regular cell culture flasks, was investigated (n=3). The Petakas and flasks were monitored 
by microscope and imaged daily for five days from 24h after seeding. The growth rate was 
determined by mean cell count per surface area. The cells cultured in Petakas experienced 
log–phase growth between 48 h and 72h reaching a maximum confluency at approximately 
60% and the cell growth plateaued after 72h (Figure 19A). In T75 flasks the cells 
experienced log–phase growth between 48 h and 96 h and reached a maximum confluency at 




Figure 19: Estimation of MIA PaCa–2 growth rate by mean cell count per surface area – visual 
representation. MIA PaCa–2 cells, seeded in Petkas and T75 cell culture flasks (75cm2) were imaged 
for five consecutive days starting 24h after seeding. The growth rate was estimated by mean cell count 
per surface area (50 images/petaka/flask; n=3).  
 
Figure 20 displays the same growth rate in single Petakas (Figure 20A) and flasks (Figure 




Figure 20: Estimation of MIA PaCa–2 growth rate by mean cell count per surface area. MIA PaCa–2 
cells, seeded in Petkas (1a – 3b) and T75 cell culture flasks (Flask 1 – 3) were imaged for five 
consecutive days starting 24h after seeding. The growth rate was estimated by mean cell count per 
surface area (50 images/petaka/flask; n=3). Mean growth in single cells was uniform, with a slight 
deviation in Petaka 3a (A). Mean growth in flask was uniform, however flask 1 was seeded with more 




4.2.5 Optimisation of timing of cell detachment with cold 1× trypsin and 10× trypsin 
To optimise planning of sonoporation studies a test was performed to determine the time it 
takes for the cells (untreated) to detach from the flask using ice–cold 1× trypsin and 10× 
trypsin. A description of the process can be found in chapter 3.6.3.1. With 1× trypsin MIA 
PaCa–2, PANC–1 and BxPC–3 took 30 min, 70 min and 2h 45 min, respectively (Table 5). 
 
Table 5: Timing of cell detachment with ice–cold 1× trypsin. 
Cell line ± time to detach cells 
MIA PaCa–2 30 min 
PANC–1 70 min 
BxPC–3 2h 45 min 
 
 
With 10× trypsin MIA PaCa–2, PANC–1 and BxPC–3 took 7 min, 21 min and 22 min, 
respectively (Table 6).  
  
Table 6: Timing of cell detachment with ice–cold 10× trypsin. 
Cell line ± time to detach cells 
MIA PaCa–2 7 min 
PANC–1 21 min 




4.2.6 Optimisation of cell detachment–western blot 
MIA PaCa–2 cells were stimulated with A23187 (1µM) + PMA (0.1µM)  for 30 min to 
induce phosphorylation. Lysates for WB were prepared according to chapter 3.7 and 30 µg, 
40 µ g and 50 µg protein extract was used to evaluate the protein level and phosphorylation 
status of the MAPK p38 (Figure 21). With 30 µg the signal was very weak prompting the 
need to use long exposure time with SuperSignalTM West Femto Maximum Sensitivity 
Substrate to develop the membrane as SuperSignalTM West Pico did not produce a signal 
(Figure 21). With 40 µg and 50 µg protein there was a clear difference in phosphorylation 
status of p38 in the stimulated sample between the different detachment methods (Figure 21). 
No phosphorylation was detected in the stimulated samples detached with pre–heated trypsin 





Figure 21: Western blot of cell detachment by cold (4oC) and warm (37oC) 1× trypsinization vs. 
scraping. MIA PaCa–2 cells were treated with A23187 (1µM) + PMA (0.1µM for 30 min (+). 
Untreated cells were kept as control (–). Cells were detached by cold 1× trypsin (4oC), warm trypsin 
(37oC) or by scraping. COX IV was used as a loading control. Western blot analysis of p38 shows a 
weak phosphorylation using 30 µg, while samples loaded with 40 µg and 50 µg shows a clear 
activation in the samples detached with ice–cold 1× trypsin.  
 
4.2.7 Optimisation of cell detachment with 10× trypsin –Viability 
In order to determine whether detaching cells with 10× trypsin affected cell viability trypan 
blue count (cell count), Hoechst 33342 (apoptosis) and WST–1 (metabolic) assay were 
performed as per chapter 3.6.3.3. Trypan blue stained cells counted within 5 min of 
detachment with 10× trypsin did not result in cell death (Figure 22A). Of the Hoechst stained 
cells, there was no difference in percent apoptosis occurring between the cell lines (Figure 
22B). The assessment of metabolic activity in live cells by WST–1 showed a relative very low 
absorbance of MIA PaCa–2 cells, but the absorbance of PANC–1 and BxPC–3 was similar 




Figure 22: 10× trypsin test – trypan blue, Hoechst 33342 and WST–1 assessment. MIA PaCa–2, 
PANC–1 and BxPC–3 were stimulated with A23187 (1µM) + Phorbol 12–myristate 13–acetate 
(PMA) (0.1µM) for 30 min and detached by cold 10× trypsinization. Cells stained with trypan blue 
(cells: trypan blue was 1:1) were counted within 5 min of detachment, while cells for Hoechst and 
WST–1 were incubated for 24h (37oC, 5% CO2) before adding Hoechst (1:1) and WST–1 (1:10). 
Hoechst images were captured using a 5×/0.6NA 20× objective coupled to an inverted Axiovert 
microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany) using Zen Pro software (Carl Zeiss 
Microscopy GmbH, Göttingen, Germany). Image exposure time was set to 32.991 ms, and the light 
source (DAPI) was set to max. The images were analysed in Fijii software (ImageJ) and figures made 
in Graph Pad Prism (GraphPad Software, La Jolla, CA, USA). Absorbance of WST–1 stained cells 
were read after 2h on a plate reader (Spectra Max Plus 384) at 450 nm and 620 nm. The results were 
analysed in Microsoft Excel (Microsoft Office 2018) and figures made in Graph Pad Prism (GraphPad 
Software, La Jolla, CA, USA). 
 
4.2.8 Optimisation of cell detachment with 10× trypsin – Western blot 
Since cell signalling is essential in this project, the relative phosphorylation status of selected 
proteins was analysed in MIA PaCa–2,  PANC–1 and BxPC-3 by WB as described in chapter 
3.6.3.3. ERK 1/2 was strongly phosphorylated in stimulated MIA PaCa–2 and PANC–1 
samples, while BxPC–3 had a relative weaker phosphorylation in the stimulated samples 
(Figure 23). p38 was only phosphorylated in stimulated BxPC–3 cells and SAPK/JNK was 
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only phosphorylated in PANC–1. MLC was not phosphorylated in any cell lines and MLC 
lacked total MLC protein (Figure 22).  
 
Figure 23: Western blot of cell detachment by 10× trypsin with three pancreatic cell lines. MIA 
PaCa–2, PANC–1 and BxPC–3 cells were treated with A23187 (1µM)  + Phorbol 12–myristate 13–
acetate (PMA) (0.1µM)   for 30 min (+). Untreated cells were kept as control (–). ERK 1/2 was 
strongly phosphorylated in the treated MIA PaCa–2 and PANC–1 samples and a weak activation in 
BxPC–3. MLC was not phosphorylated in any cell line and total MLC appears absent in MIA PaCa–2. 
p38 was weakly phosphorylated in stimulated BxPC–3 cells, and SAPK/JNK was phosphorylated in 
stimulated PANC–1 cells.  
 
 
4.2.9 Optimisation of western blotting 
To determine the presence and phosphorylation status of chosen signalling proteins in MIA 
PaCa–2 the cells were stimulated with various chemicals, known as positive controls (Figure 
24). The test was also to ascertain whether the antibodies corresponding to chosen proteins 
worked in MIA PaCa–2 cells. WB was performed with 40 µg protein extract. ERK 1/2 was 
stimulated (phosphorylated) by all stimuli but was markedly stimulated by A23187+PMA 
(Figure 24). SAPK/JNK resulted with phosphorylation in the control only, while p38 was 
phosphorylated by TNFα. eIF2α was phosphorylated in both the control and stimulated 
sample (A23187). Both MUPT1 epitopes (Ser853/Ser696) were phosphorylated in both the 
control and stimulated sample (A23187) (Figure 24). All tested antibodies worked, although 
some antibodies require SuperSignalTM West Femto Maximum Sensitivity Substrate for 
development of the membranes due to weak signal.  
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Figure 24: Validation of antibodies for sonoporation studies with MIA PaCa–2 – Western blot. MIA 
PaCa–2 cells were treated with Tumour necrosis factor (TNFα; 15 min; T1), A23187 + Phorbol 12–
myristate 13–acetate (PMA; 30 min; T2), or A23187; 4h; T3). 40 µg protein was used for western blot. 
ERK 1/2 was stimulated (phosphorylated) by all stimuli but was markedly stimulated by 
A23187+PMA. SAPK/JNK was phosphorylated in the control only, while p38 was phosphorylated by 
TNFα. eIF2α was phosphorylated in the control and stimulated sample (A23187). MYPT1 (Ser853/ 
Ser696) was phosphorylated both in the control and stimulated sample (A23187).  
 
4.2.10 Optimisation of incubation time following sonoporation 
To determine the optimal incubation time to detect cell signalling in MIA PaCa–2 cells, 
following sonoporation in Petaka, a test was performed. The process  is described in chapter 
3.6.4. ERK 1/2had a time-dependent increase in phosphorylation, peaking at 1h, while MLC 
showed no phosphorylation before 2h, where the signal was strong (Figure 25). eIF2α had a 
time–dependent steady increase in phosphorylation (Figure 25). Based on these results it was 
determined to proceed with 2h incubation time for further sonoporation studies of MIA PaCa–
2.  
Figure 25: Western blot of test of incubation time post sonoporation of MIA PaCa–2. Cells were 
sonoporated at 358 mW/cm2 with Sonazoid MBs (5.6 µL/mL). for 5 min and incubated (5% CO2 at 
37˚C) for 5 min, 1h or 2h. Control was not sonoporated. ERK 1/2had a time-dependent increase in 
phosphorylation, peaking at 1h, while MLC showed no phosphorylation before 2h, where the signal 




4.3 Sonoporation of MIA PaCa–2 cells 
4.3.1 Viability sonoporated MIA PaCa–2 
MIA PaCa–2 cells were treated with three different US conditions with and without Sonazoid 
MBs as described in chapter 3.6.6. The cells treated with US only differed in total cell count, 
of which the Low US sample had a higher cell count, and none of the samples had a 
significant number of trypan blue stained cells (Figure 26A). Of the samples treated with US 
and MBs the total cell count was again higher for Low US compared the other samples, and 
here more cells were stained by trypan blue (Figure 26B). The Hoechst assay showed that in 
cells treated with US only (– MBs) the Low and Medium US samples had a higher percentage 
apoptotic cells, compared to the control, while High US had less than half the percentage of 
apoptotic cells (Figure 26C). Of the Hoechst stained cells treated with US and MBs the 
control had the most apoptotic cells and the treated samples varied in the percentage of 
apoptotic cells (Figure 26D). The WST–1 metabolic assay showed that in cells only treated 
with US (– MBs) the control had a very low absorbance compared to the treated samples, 
which had a decreasing absorbance with increasing US intensity (Figure 26E). The 
absorbance of the samples treated with US and MBs was very similar, with a slight increase 







Figure 26: Viability assays of sonoporated MIA PaCa–2 cells. MIA PaCa–2 cells, cultured in Petaka 
3G bioreactors, were sonoporated at Low (3mW/cm2), Medium (50mW/cm2) and High (358mW/cm2) 
ultrasound (US) with/without Sonazoid MBs (5.6 µL/mL) and incubated at 37oC 5% CO2 for 2h after 
sonoporation. Cells were detached by ice–cold 1× trypsin. Trypan blue count performed immediately 
after detachment, while cells for Hoechst and WST–1 were incubated for 24h (37oC, 5% CO2) before 
adding Hoechst (1:1) and WST–1 (1:10). Images were captured using a 5×/0.6NA 20× objective 
coupled to an inverted Axiovert microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany) 
using Zen Pro software (Carl Zeiss Microscopy GmbH, Göttingen, Germany). Image exposure time 
was set to 32.991 ms, and the light source (DAPI) was set to max. The images were analysed in Fijii 
software (ImageJ) and figures made in Graph Pad Prism (GraphPad Software, La Jolla, CA, USA). 
Cells for WST–1 were incubated for 2h before reading the absorption on a plate reader (Spectra Max 




4.3.2 Western blot sonoporated MIA PaCa–2 
MIA PaCa–2 cells were treated with three different US conditions with and without Sonazoid 
MBs as described in chapter 3.6.6. ERK 1/2 was weakly phosphorylated without MBs and 
showed a stronger phosphorylation with increasing US intensity with MBs (Figure 27). p38 
was only weakly phosphorylated at High US with MBs and SAPK/JNK was not 
phosphorylated in any samples. eIF2a and STAT3 were phosphorylated in all samples, which 
show that these are constitutively active in these cells. For eIF2α this was also seen during 
optimisation of western blot (previous section).  S6 showed an increase in phosphorylation at 
higher US intensities. MLC was weakly phosphorylated without MBs and a clear increase at 
High US with MBs. No phosphorylation was observed for both MYPT1 (Ser853) and 
MYPT1 (Ser696) (Figure 27). 
Figure 26: Western blot analysis of sonoporated MIA PaCa–2 cells. MIA PaCa–2 cells, cultured in 
Petaka 3G bioreactors, were sonoporated at Low (3 mW/cm2), Medium (50 mW/cm2) and High (358 
mW/cm2) ultrasound (US) with and without Sonazoid MBs (5.6 µL/mL), incubated at 37oC 5% CO2 
for 2h following sonoporation. Cells were detached by ice–cold 1× trypsin. ERK 1/2 was weakly 
phosphorylated without MBs and had a stronger phosphorylation with increasing US intensity with 
MBs. p38 had only a weak signal at High US with MBs and SAPK/JNK was not activated in any 
samples. eIF2a and STAT3 were phosphorylated in all samples, while S6 showed an increase in 
phosphorylation at higher US intensities. MLC had a weak phosphorylation without MBs and a clear 
increase in phosphorylation at High US with MBs. MYPT1(Ser853) had a weak activation, while 




The mechanisms and biological effects of sonoporation are well studied (27-29), however 
there is insufficient data on the intracellular effects of sonoporation. Cell signalling induced 
by sonoporation has been investigated previously in suspension cells, such as in leukemia cell 
lines (20, 30, 31), but in pancreatic cell lines there is little research into the intracellular 
effects of sonoporation. 
This project addresses this gap in current research, namely investigating signalling proteins 
and pathways affected by sonoporation in pancreatic cell lines, aiming to identify biomarkers 
for PDAC that ca be used to optimise sonoporation therapy. An important part of this 
investigation is in vitro optimisation of sonoporation. Numerous of parameters had to be 
optimised before continuing to sonoporation of pancreatic cell lines. Studying sonoporation in 
adherent cell lines, such as pancreatic cell lines, entails different conditions that can affect the 
outcome, for example detaching the cells from the flask to be able to analyze them. Therefore, 
the initial investigation of intracellular effects induced by sonoporation was performed with 
the leukemic cell line MOLM–13. With previous results to refer to (20), it was possible to 
optimise treatment parameters, as well as getting an indication of which signalling pathways 
were induced by sonoporation. Clearly, there was no guarantee that the same pathways would 
be induced in pancreatic cell lines, nevertheless, it was a good starting point. Also, since the 
custom–built US technology we used to treat adherent cell lined was not yet available at the 
beginning of the project, it was natural to start with the suspension cell line MOLM–13 as a 
model system. For suspension cells there was an US machine (also custom–made) available. 
 
5.1 Choice of signalling pathways 
There are almost endless signalling proteins and pathways to choose from when studying cell 
signalling. The choice is slightly narrowed by one of the objectives of this current project, 
which was to identify biomarkers to identify a successfully sonoporated cell that ca be used to 
optimise sonoporation therapy. Thus, signalling proteins involved in cellular stress response, 
the induction of apoptosis and survival are interesting. As a starting–point, signalling proteins 
known to have been induced by sonoporation in previous studies were investigated. These 
include the MAPK proteins ERK 1/2, p38 (24), and SAPK/JNK  and the molecular switch for 
global protein translation eIF2a (31). In studies of adherent pancreatic cell lines proteins 
involved in adherence and migration is interesting, such as STAT3 (migration/invasion) (40) 
and MLC2 and MYPT, which are part of the Rho/ROCK pathway that mediates 
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cytoskeletal reprogramming during invasion and metastasis (48). Ribosomal protein S6 is 
downstream of the PI3K–mTOR pathway which has cross-talk with the UPR (Figure 7). ER–
stress, which activates the UPR, has been shown to be induced by sonoporation (31), and was 
therefore included in this current investigation.   
  
5.2 MOLM–13 
MOLM–13 cells were treated with three US intensities and MBs (sonoporated). Cells were 
also treated with US alone to evaluate its effect on the cells. Protein were extracted for WB 
analysis of chosen signalling proteins. Three different viability assays, trypan blue, Hoechst 
33342 and WST–1, were considered as an assessment of cell viability following sonoporation. 
COX IV was used as a loading control. The protocol is described in detail in chapter 3.5.1. – 
3.5.3. 
 
5.2.1 Trypan blue 
The first viability assay, trypan blue, is a DNA–binding dye that only stains dying and 
apoptotic cells (72). For MOLM-13 trypan blue was used for total cell count following 
treatment, as well as an assessment of the number of dead cells. Trypan blue was employed 
both immediately following treatment and after 24h to assess whether the treatment had 
affected the cells ability to proliferate (measured by change in cell concentration). Cell death 
can also be assessed by a range of other methods. However, the trypan blue assay provides 
immediate information on cell concentration and can be used to measure change in cell 
proliferation. Furthermore, it is a quick way to evaluate cell death. Therefore, it was decided 
to employ trypan blue for sonoporation studies in both MOLM–13 and pancreatic cell lines.  
 
5.2.2hoechst 33342 
The second viability assay used in this project, Hoechst 33342, is also a fluorescent DNA–
binding dye. Hoechst not only stains apoptotic cells in different stages, early, late apoptotic 
and necrosis, but also mitotic cells (73). This assay allows for a direct, visual evaluation of 
cell morphology, compared to trypan blue stain, which only provides a percentage of dead 
cells in the sample. Hoechst 33342 was included to assess whether cells died by apoptosis. 
Traditionally, the apoptotic cells are counted manually in the microscope, however, there are 
many disadvantages using this method. The fluorescent dye fades when exposed to light over 
time, therefore, if the user takes too long the apoptotic cells may no longer be distinguishable 
Silje	Maria	Sundøy	 	 University	of	Bergen	
	 65	
from the viable cells, and which cells are in fact apoptotic is a subjective evaluation. 
However, if images are captured this can be documented and the analysis double-checked. 
Using images, it was possible to get a more accurate result, compared to manual counting. 
The method is not perfect, however, also here, the program may not be able to identify all 
cells, or to distinguish two adjacent cells from each other if they are too close. Adjustments 
are made manually to correct for contrast to enable the software to identify each cell as a dot, 
then, the dots are counted by the software. Consequently, resuspension of the cells 
immediately before seeding, and seeding density, is very important using this semi–automated 
method. With too many clustered and overlapping cells the software will be unable to identify 
single cells for total cell count. Furthermore, the identification of apoptotic cells is also here a 
subjective evaluation by the user, however, the advantage of having images stored for 
analysis at a later time–point enables the user to take his/her time to do the analysis properly. 
Furthermore, it is important to be able to identify the different stages of apoptosis and to be 
able to distinguish apoptotic cells from mitotic cells, which also are stained by Hoechst.  
 
5.2.3 WST–1 assay 
A third viability assay was considered for MOLM–13 studies, namely the WST–1 based 
metabolic assay, which provides an estimation of number of cells and of metabolically active 
cells in a treated sample. Here, the cells that survive the treatment are evaluated, as opposed 
to assessing cell death. The WST–1 salt changes colour when metabolised by the cells and the 
absorbance of light passing through the sample is measured. Resuspension of the cells and 
seeding density are important in this assay as well. If the cells are seeded too densely the 
results may be false because the reaction is saturated (WST–1 reagent is metabolised) before 
the absorbance is read. Additionally, it is important that all samples have the same seeding 
density. Therefore, a test was performed where different cell concentrations (between 0.5×106 
and 1.0×106) of MOLM–13 cells (untreated) were seeded and subject to the WST–1 assay. At 
0.8×106cells (Figure 13) the reaction is saturated, and the curve flattens. This cell 
concentration is interesting due to the experimental setup of sonoporation of MOLM–13 cells. 
In order to have enough cells to make sufficient lysate for WB analysis, 0.41×106 cells/mL 
were used in the sonoporation experiment with MOLM–13. For experiments the cells are 
seeded when they are in log–phase, and during the 24h incubation period following treatment 
cell number may double, and then, according to these results, the WST–1 reagent is saturated 
by too many cells (Figure 13). In addition, the absorbance was low. Therefore, it was 
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determined to not use this assay for MOLM–13 studies. Nevertheless, cell viability of 
MOLM–13 cells were evaluated by trypan blue count and Hoechst 33342.  
 
5.2.4 Sonoporated MOLM-13 – Western blot and viability 
The treated MOLM–13 cells were also analysed by western bot where the relative 
phosphorylation status of selected signalling proteins was evaluated.  
 
5.2.4.1 MAPK pathway 
p38, belonging to the MAPKs, was downregulated in Low and Medium US, but upregulated 
in High US samples without MBs (Figure 15). The MAPK are part of a signalling cascade 
that can be activated by many extracellular signals, stress signals, such as pro–inflammatory 
cytokines and for example the epidermal growth factor (EGF), which binds to the EGF 
receptor (EGFR) initiating a signalling cascade that activates the MAPK. However, 
intracellular signals may also activate the MAPK. There is substantial cross–talk between 
signalling pathways, and MAPKs are also activated by ER–stress via  the UPR (35). The UPR 
activates p38 via ASK1 and MKK4 (Figure 7).  One study found that ER–stress proteins 
were activated by sonoporation (20), and also here, it is possible that p38 is activated by ER–
stress via the UPR. After 5 min of sonoporation cells were phosphorylated by High US 
without MBs, indicating that High US alone has an effect on the cells, and with MBs added 
the phosphorylation increased with increasing US intensity (Figure 15). Analysis of p38 2h 
after sonoporation showed that with MBs added, however, there was no phosphorylation of 
p38 without MBs, while the control, Medium and High US samples with MBs were 
phosphorylated (Figure 15). The results suggest that the phosphorylation is induced at higher 
US intensities with MBs. Importantly, the WB was performed once, which is not sufficient to 
draw any definite conclusions. Both cell proliferation or cell cycle arrest can be stimulated by 
the activation of p38, depending on the kinetics of activation and downstream signalling 
pathways activated (35). In sonoporated cells with MBs at Medium and High US the cell 
proliferation ability was reduced, and some cell death occurred (Figure 14). Cell death, 
assessed by the percentage apoptotic cells, showed that there was no difference between the 
treated samples and the control without MBs, indicating that US alone does not have an 
effect. However, with MBs added there was an increase in percentage apoptotic cells (Figure 
14E), also reflected in the reduced proliferation ability (Figure 14D). With this in mind, these 
results indicate that p38 may be involved in the reduction of proliferation. p38 also mediates 
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cell cycle arrest (Figure 7), although, this was not investigated in this thesis cell cycle arrest 
has been shown to be induced by sonoporation (30). The phosphorylation at higher US 
intensities with MBs indicate activation, which may influence cell cycle arrest. However, the 
WB analysis of p38 is inconsistent and needs to be confirmed.  
 
ERK 1/2, one of the MAPKs, was increasingly phosphorylated 5 min after sonoporation both 
without and with MBs, but after 2h the signal decreased (Figure 15). ERK 1/2 is activated 
extracellularly by hormones, integrins and practically all growth factors and intracellularly by 
the UPR via ER–stress activation (35). ERK 1/2 activation promotes cell proliferation, 
differentiation and cell survival. However, the fact that proliferation ability was reduced with 
MBs added (Figure 14), may be influenced by any number of other signalling proteins. 
Though, the increasing ERK 1/2 phosphorylation (Figure 15) implies that ERK 1/2 may be 
induced by sonoporation initiating proliferation and cell survival pathways. The estimation of 
percentage apoptotic cells showed no difference between treated samples and the control 
without MBs (Figure 14E), consistent with proliferation and survival signals initiated, while 
the percentage apoptotic cells increased with increasing US intensity with MBs (Figure 14F), 
which is reflected in the reduced ERK 1/2 phosphorylation after 2h (Figure 15).  
 
The third MAPK, JNK showed no phosphorylation 5 min after sonoporation, but was 
phosphorylated after 2h with and without MBs (Figure 15). There was no difference between 
the control and samples, indicating that sonoporation had no effect (Figure 15). JNK, as p38, 
is activated by pro–inflammatory cytokines, oxidants, ER–stress and other cellular 
extracellular stresses (35) (Figure 7) in addition to the UPR (intracellularly). JNK is 
phosphorylated by MKK4, which also activates p38, and MKK7 via ASK1. ASK1 is 
activated by the UPR, or by MEKK1, which is activated by extracellular signals. JNK 
promotes apoptosis, autophagy, but also cell survival. The fact that JNK was not 
phosphorylated after 5 min of sonoporation can indicate that it has a delayed response. Cell 
proliferation, measured by trypan blue, showed that only cells with MBs were affected by the 
treatment (Figure 14). Additionally, the percentage apoptosis, measured by Hoechst 33342, 
showed the same trend, namely that only cells with added MBs were influenced by the 
sonoporation. In relation to JNK signalling, no phosphorylation at 5 min and the 
phosphorylation at 2h may indicate that cell survival signals were activated initially, but after 





5.2.4.2 UPR pathway 
The UPR, activated by ER–stress, also activates an important signalling protein called eIF2α, 
which upon phosphorylation attenuates global protein translation (33). This signalling 
cascade, depicted in Figure 6, starts with the activation of PERK, an ER–stress 
transmembrane sensor that phosphorylates eIF2α, which leads to an increase in the selective 
translation of the mRNA encoding for ATF4, a transcription factor that induces the expression 
of several genes, including apoptosis and autophagy and GADD34. GADD34 works as a 
negative feedback on eIF2α dephosphorylating it during prolonged ER–stress. In sonoporated 
MOLM–13 cells no phosphorylation was detected in after 5 min, but after 2h there was a 
clear increase in phosphorylation with increasing US intensity (Figure 15). After 24h the 
Medium and High US samples with MBs had a reduced proliferation ability, compared to the 
control, correlating with the increasing phosphorylation of eIF2α after 2h (Figure 14D). This 
indicates that eIF2α had a delayed activation and global protein translation was 
downregulated, but also that the UPR was initiated. Activation of PERK, upstream of eIF2α, 
has been shown to have a delayed response to stress (31), which correlates with the WB 
analysis of eIF2α above. As for the assessment of percentage apoptosis in relation to eIF2α, 
the author refers to the above explanation that the activation of the UPR, which has a myriad 
of downstream signals that affects apoptotic signals. The results, however, needs to be 
confirmed.  
 
5.2.4.3 PI3K–mTOR pathway 
The WB analysis showed that of Ribosomal protein S6 was phosphorylated in all samples, 
with/without MBs at 5 min and 2h, including the control (Figure 15). This suggests that S6 is 
constitutively active in MOLM-13. As the viability assays (proliferation by trypan blue and 
apoptosis by Hoechst 33342) indicate, that there was only an evident effect in cells with MBs 
after 24h of sonoporation (Figure 14A–F), suggesting a delayed response not detectable after 
2h. Sonoporation has been shown to influence ER-stress (31), therefore, further investigation 
of the effect sonoporation may have on S6 should include sampling at different time–points 





5.2.4.4 JAK/STAT pathway 
STAT3 (Tyr705) was not phosphorylated 5 min post sonoporation, however, after 2h the 
control and Low US intensity (74 mW/cm2) were weakly phosphorylated (Figure 15). The 
results from 5 min post sonoporation appear credible since STAT3 (total protein) had even 
loading in all samples. The samples from 2h post sonoporation, however, were unexpected. 
Total STAT3 without MBs is absent and with MBs the loading is uneven, thus confirmation 
of the results is essential. STAT3 is activated by phosphorylation at Tyr705 (74), one of the 
epitopes tested here, indicating that STAT3 had an immediate downregulation by 
sonoporation, which returns after 2h (Figure 15). This suggests that sonoporation may have 
an immediate, but brief effect on STAT3 downregulating it, which is interesting since 
blocking STAT3 has been shown to slow tumour growth (40). Phosphorylated STAT3 
(Ser727), which is associated with transcription and cell survival (75), though, was weakly 
phosphorylated in all samples 5 min post sonoporation (Figure 15). After 2h all samples were 
phosphorylated, indicates that sonoporation had little effect on STAT3. Considering that 
STAT3 is a constitutively active transcription factor in many cancers (40), including acute 
myeloid leukaemia (AML), from which the MOLM–13 cell line originates (76), stimulation 
might just aggravate the constant STAT3 signalling in MOLM–13. STATs regulate cellular 
growth, differentiation, survival and development, and with a constitutively active 
ligand/receptor engagement, abnormal STAT signalling may contribute to tumour 
development by stimulating cell cycle progression and/or cell survival (76). STAT3 alone 
probably cannot cause tumour progression, however, it plays an important role being 
constitutively turned on in many cancers (40).   
 
5.2.5 Concluding remarks MOLM–13 
The initial experiments with MOLM–13 enabled us to establish protocols and test the 
methods used to analyse sonoporated cells. It was demonstrated that it is possible to induce 
cell signalling with sonoporation and that we were able to detect a signal. shown 
 
5.3 Pancreatic cell lines 
5.3.1 Ultrasound treatment of cells – challenges 
When studying cell signalling there are several aspects to be aware of that can affect the 
signalling resulting in false or skewed results. This applies particularly to adherent cells, 
which has to be detached from its substrate to be analysed. Trypsin is an enzyme that detaches 
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the cells by cleaving peptides on the cell surface, however, trypsin is not selective and can 
affect cell surface epitopes (60), which can have a downstream effect on intracellular 
signalling by either activating or de–activating cell surface receptors (59). For example, 
trypsin was fond to activate PAR2, which stimulates the MAPK pathway, including MAP 
phosphatase, which reduce p–ERK level induction by other receptors (59). Furthermore, one 
study determined that trypsin induced RhoA signalling (64), and Blc2, p53 and p33 were all 
found to be up or downregulated by trypsin (77). We used heated trypsin (37oC) for cell 
passaging and initially also for cell detachment following treatment, since it is at this 
temperature it works optimally (60). However, cold trypsin, which is still 50% active at 
around 4oC, would be a better option for cell signalling studies as it affects the surface 
epitopes to a lesser degree since the tyrosin kinases remain inactive at this temperature (59). 
Therefore, we have investigated the effect of trypsin on the cells, comparing cold and warm 
trypsinization. Cell detachment by scraping was also included in the test to check its effect on 
signalling. Although it is possible to detach cells in a Petaka using a magnet (62), we did not 
have the available technology to do this, so we had to utilise enzymatic cell detachment. See 
discussion of testing 1× and 10× trypsin below (chapter 5.3.6 – 5.3.8.2). Furthermore, the 
lack of commercially available technology to treat cells cultured in a Petaka with US was a 
time–limiting factor. It is possible to treat adherent cells in regular cell culture plates; 
however, we chose to use the hypoxic bioreactor Petaka 3G in order to mimic the severely 
hypoxic PDAC tumour. Using the Petaka the need for a hypoxic chamber is eliminated.  
 
5.3.2 Optimisation of cell lysis 
In order to determine how many WBs could be performed with 1×106 MIA PaCa–2, PANC–1 
and BxPC–3 cells were quantified using 50 µl RIPA buffer (Table 4). This was important to 
assess the number of experiments to prepare sufficient lysate to investigate the chosen 
proteins of interest from one experiment. The protein concentration of the different cell lines 
varied: MIA PaCa–2 (2.774 µg/µl), PANC–1 (3.495 µg/ µl) and BxPC–3 (2.208 µg/µl), which 
provided 4, 5 and 3 WBs, respectively (Table 4). Since the protein concentration varied, the 
WBs were planned accordingly.  
 
5.3.3 WST–1 – Optimisation of cell number seeded and incubation time – MIA PaCa–2 
As explained previously (chapter 3.3.1.3) the WST–1 assay provides an estimation of 
metabolically activity in the cells. The WST–1 salt is metabolized by the cells and thereby 
Silje	Maria	Sundøy	 	 University	of	Bergen	
	 71	
changes colour. The disadvantage of this assay is that if the cell concentration is too high the 
WST–1 reagent will be saturated before the reaction is finished and the results will be 
unreliable. Thus, to optimise this assay for MIA PaCa–2 cells were sonoporated (358 
mW/cm2, 5 min) and different cell concentrations (1×103 – 6.4×104) were seeded and 
incubated for 24h. The cells were then incubated for 1, 2 or 4h after adding the WST–1 
reagent. The cells incubated for 1h had a rapid increase in absorption between 0.8×104 and 
1.61×104 cells seeded, and then the curve plateaus, indicating the reaction is saturated 
(Figure 16). Cells incubated for 2h had a steadier increase in absorption with increasing cell 
number seeded, but with a rapid increase in absorption between 3.2×104 and 6.4×104 cells 
seeded. When incubated for 4h the absorption increased more rapid after 0.8×104 cells 
seeded. Considering that this test was only performed once it is difficult to draw a conclusion, 
however, based on these results it was decided to continue with 3.21×104 cells incubated for 
2h in further studies with MIA PaCa–2, as under these conditions the increase in absorption 
was steady.  
 
5.3.4 Optimisation of viability assays 
To get an indication on how the cells’ viability was affected by sonoporation, and to 
determine the optimal seeding density, a test was performed using High US, Serum–starvation 
(positive control) and untreated MIA PaCa–2 cells. Trypan blue, Hoechst 33342 and WST–1 
(both assays: 3.2×104 cells/well) assays were included in the test. There were barely any 
trypan blue stained cells in any of the samples (data not shown). The WST–1 assay revealed 
no significant difference between the control and High US, while the starved sample showed 
a significant reduction in metabolic activity, compared both to the control and High US 
(Figure 17A). Keeping in mind that the cells were incubated for 24h before performing the 
assay itself, may have allowed the cells in High US sample to recover from sonoporation. In 
contrast, the sample with starved cells showed a significant reduction in absorption, 
suggesting that starvation affected the cells. It is well known that serum–starvation can affect 
the viability of cells. Partial starvation may strengthen some sub–populations (in MCF7 breast 
cancer cell line), but complete serum–starvation will affect their ability to proliferate (78). 
The starvation affects the rate of DNA synthesis after 20 h of starvation, and mitotic activity 
is inhibited (79). Serum–starvation can also activate apoptotic pathways, resulting in cell 
death (80). In the current test the cells were starved completely for 24h, therefore, the 
reduction in metabolic activity in the starved cells can likely be attributed to the lack of 
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proliferation due to inhibition of mitotic activity, as well as induction of apoptosis. High US 
did barely affect the cells’ metabolic activity, compared to the control (Figure17A), however, 
considering that the cells are incubated for 24h following sonoporation the cells may have 
recovered from the treatment overnight. It was decided that 3.2×104 cell/well was acceptable 
for WST–1 assay to evaluate MIA PaCa–2 cells in further studies. The images of the Hoechst 
stained cells, processed as explained earlier (chapter 3.3.2.1), correlates with the WST–1 
analysis (Figure 17B). The control and High US samples appear similar in cell density, while 
that starved sample had fewer cells, indicating cell death and/or lack of proliferation occurring 
during the 24h incubation period following treatment. The test also revealed that the seeding 
density was too high in the control and High US samples for the software to be able to 
distinguish between single cells, even with manual adjustments of contrast and threshold. In 
fact, it was possible to count the serum–starved cells (Fig 17B, but it was not performed since 
it was not possible to quantify the control and High US and, therefore, there would be no 
ground for comparison. As 3.2×104 cells was too dense to distinguish single cells, a new 
Hoechst test was performed seeding 0.8×104 and 1.6×104 cells/well (Figure 18). The images 
were evaluated visually due to poor image quality, as opposed to counting the cells with the 
software. For the purpose of determining seeding density this was sufficient. Based on a 
sample of images (three/well) representing the average cell density, it was decided to proceed 
with 1.6×104 cells/well in future Hoechst 33342 assays with MIA PaCa–2 (Figure 18).  
 
5.3.5 Optimisation of growth rate 
Culturing cells is normally done in cell culture flasks, which have ventilated caps allowing 
exchange of gasses. The Petaka, however, has minimal gas exchange, it is essentially a 
hypoxic bioreactor (81), hence it was assumed that the cells would behave differently in terms 
of growth rate. It was important to find optimal conditions for cell growth in relation to 
treating the MIA PaCa–2 cells with sonoporation to avoid the cells turning too hypoxic and 
entering senescence. The main objective was to ascertain when the cells experience log–phase 
growth. In order to determine in which time–period the cells in Petakas experience log–phase 
growth the cells were cultivated until they reached their maximum confluency, which is when 
they run out of space, nutrients and/or oxygen, resulting in slowing of DNA synthesis rate and 
inhibition of mitotic activity (79). MIA PaCa–2 cells were cultivated in Petakas and T75 
flasks over the course of 6 days to compare the growth rate between the two cell culture 
methods. The growth rate was calculated by estimating the percentage surface area covered 
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by the cells in Petakas and flasks by imaging the cells. The cells in Petakas experienced log–
phase growth between 48 and 72h (Figure 19A), while in the flasks log–phase growth was 
reached between 24 and 96 h (Figure 19B). Cells in Petakas reached full confluency around 
60% surface area covered and the growth plateaued (Figure 19A). Cells in the flasks 
continued to grow further 24h, compared to the cells in Petakas, and reached full confluency 
around 80% of surface area covered by the cells (Figure 19B). 
Cell growth in single Petakas was relatively even, but cells in one Petaka (Figure 20A– “3a”) 
that appeared to experience less growth, compared to the rest. This might be due to an air 
pocket observed in this Petaka. When seeding cells in Petakas they are first placed in a 
horizontal position in the incubator for 24h for the cells to adhere, and then placed vertically 
for continued incubation. Between 24 and 48 h an air pocket appeared in the top of the 
Petaka, resulting in no medium covering the cells in this area, possibly drying and killing 
these cells. The air was removed at 48 h and fresh medium was refilled (2 mL) to ensure cell 
growth. Nevertheless, the mean growth between the Petakas was quite similar (Figure 20A).  
Cell growth in single flasks was also relatively even in rate (Figure 20B). The deviation here 
was that flask # 1 appears to have been seeded with a higher cell number, compared to flask # 
2 and 3 (Figure 20B). From these observations, it was decided to treat cells in Petakas 
between 48 and 72h of seeding as the cells experienced log–phase growth between those 
time–points.  
 
5.3.6 Optimisation of timing of cell detachment with cold 1× trypsin 
The time is takes untreated cells to detach from the flask with cold 1× trypsin and 10× 
trypsin was tested in three pancreatic cell lines; MIA PaCa–2, PANC–1 and BxPC–3. With 
1× trypsin MIA PaCa–2 cells were detached by 30 min on ice, while PANC–1 and BxPC–3 
took 70 min and 2h 45 min, respectively (Table 5). With 10× trypsin MIA PaCa–2, PANC–1 
and BxPC–3 took 7 min 21 min and 22 min, respectively (Table 6). Due to the complex and 
time–consuming experimental setup of the main experiment, sonoporation at different US 
intensities with/without MBs, it would be impractical to include PANC–1 and BxPC–3 in 
further studies. Furthermore, it is not known whether incubation with trypsin on ice over such 
long periods of time affects the results. However, due to the potential time saved with using 
10× trypsin for cell detachment, this was tested before excluding PANC–1 and BxPC–3. 
Between 7 and 22 min is feasible in a large experiment, in terms of the timing of all the steps 
after cell detachment, including seeding of cells for viability assays and protein extraction. 
Especially for PANC-1 and BxPc-3 detachment with more concentrated trypsin is necessary 
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to do signalling studies in these cell lines. However, before determining whether it was 
feasible to continue with all three cell lines, WB analysis was performed for 1×trypsin and 
10× trypsin, in addition to viability testing of the cells detached with 10× trypsin.   
 
5.3.7 Optimisation of cell detachment with cold 1× trypsin – western blot 
As mentioned above, it is known that trypsin may affect cell signalling by cleaving cell 
surface receptors (59, 82), including integrins, which are implicated in activation of several 
pathways (Figure 7) (47). Since investigating cell signalling was the main objective of this 
project, consequently, examining the effect on signalling of different cell detachment methods 
was essential. Three detachment methods cold 1× trypsin, pre–heated 1× trypsin and scraping 
were then tested in MIA PaCa–2 (Figure 21). The cells were stimulated with A23187 (1µM)  
+PMA (0.1µM)  for 30 min, a combination of stimuli known to induce phosphorylation. The 
cells were detached as described in chapter 3.6.3.2. Included in this test was also testing 
different amounts of protein extract for WB, as different cell lines may express different 
levels of the various proteins. For example, p38, JNK2 and c–Jun have been found to be 
upregulated in the cervical cancer and HeLa cells, compared with levels in non–cancerous 
tissues (83). Therefore, 30 µg, 40 µ g and 50 µg protein extract were used to evaluate the 
protein level and phosphorylation status of the MAPK p38. There was a relatively weak 
phosphorylation detected using 30 µg/well prompting the need to use long exposure time with 
the more sensitive SuperSignalTM West Femto Maximum Sensitivity Substrate to develop the 
membrane as no signal was detected using SuperSignalTM West Pico (Figure 21). There was a 
clear difference in phosphorylation status of p38 between the different detachment methods. 
Using 40 µg and 50 µg protein for cell detachment with ice–cold 1× trypsin resulted in 
phosphorylation of p38 in the stimulated sample (Figure 21). However, no phosphorylation 
was detected in the stimulated samples detached with pre–heated trypsin or by scraping 
(Figure 21), which was unexpected. Therefore, in further WBs 40 µg protein was used per 
well for MIA PaCa–2 cells, and all cell detachment of treated cells was performed with ice–
cold trypsin (except cell passaging) from this point forward. This test confirms that 
optimisation is particularly important in signalling studies.  
 
5.3.8 Optimisation of cell detachment with cold 10× trypsin  
The three cell lines MIA PaCa–2, PANC–1 and BxPC–3 were stimulated with A23187 (1µM)   
+ PMA (0.1µM)  for 30 min to induce phosphorylation. The cells were detached by cold 10× 
trypsinization as described in chapter 3.6.3.2. Cells were harvested for trypan blue count, 
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Hoechst and WST–1 assays and cells were prepared for WB as previously described (chapter 
3.3.1 –3.3.3) (1.6×104 cells/well for Hoechst 33342). 
 
5.3.8.1 Optimisation of cell detachment with cold 10× trypsin – viability  
Few cells were stained by trypan blue, indicating no immediate toxic effects resulting from 
this harsher treatment (Figure 22A). The uneven cell number between cell lines may be due 
to poor resuspension of cells before harvesting cells for the assay. The low number of trypan 
blue stained cells indicate that 10× trypsin detachment did not affect the cells to a large 
degree. The Hoechst 33342 analysis showed no difference in percentage apoptosis between 
the cell lines (Figure 22B). The assessment of metabolic activity in live cells by WST–1 
showed a relative very low absorbance of MIA PaCa–2 cells, but the absorbance of PANC–1 
and BxPC–3 was similar (Figure 22C).  The inconclusive were unexpected and needs to be 
confirmed. To get a better impression of how 10× trypsin might influence signalling WB was 
performed with selected proteins. 
 
5.3.8.2 Optimisation of cell detachment with cold 10× trypsin – western blot 
ERK 1/2 was strongly phosphorylated in stimulated MIA PaCa–2 and PANC–1 samples, 
while BxPC–3 was relatively weaker phosphorylated in the stimulated samples (Figure 23). 
The results for stimulated BxPC–3 sample are blurred. This might be due to a deformed well 
used to load the protein, but this can also have happened when applying the membrane to the 
gel during transfer causing smudging of this sample. Regardless, there is a weak 
phosphorylation of ERK 1/2 in BxPC-3 (Figure 23). ERK 1/2 mediates cell proliferation, 
survival differentiation. When cells are stressed survival mechanisms are initiated, which 
might explain the induction of phosphorylation across all cell lines. p38 was only weakly 
phosphorylated in stimulated BxPC–3 cells. Recalling that p38 was phosphorylated in MIA 
PaCa–2 cells tested with cold 1× trypsin (Figure 22), it is possible that cold 10× trypsin 
indeed affected p38 signalling. Trypsin has been found to affect MAPK signalling, including 
p38 (84). SAPK/JNK was only phosphorylated in stimulated PANC–1 cells (Figure 23). JNK 
mediates apoptosis and autophagy and cell survival (35). The lack of detected 
phosphorylation in MIA PaCa–2 and BxPC–3 might indicate that they are more sensitive to 
trypsin than PANC–1, or that it is more difficult to activate this pathway in these cell lines. 
No phosphorylation was detected in MLC in any cell lines and protein lading was not 
successful for MIA PaCa-2 (Figure 23). The lack of total MLC in MIA PaCa–2 could be an 
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error, or MLC in MIA PaCa–2 is possibly extremely sensitive to trypsin. The Ponceau red 
staining of the membrane showed even loading of protein (Figure 28 – Appendix), therefore, 
the lack of total MLC protein is unknown. Due to the inconsistent results from the 10× 
trypsin test, including viability and WB analysis, it was decided to continue with cold 1× 
trypsin for cell detachment for the purpose of this current project.  
 
5.3.9 Optimisation of western blotting 
To determine the presence and phosphorylation status of chosen signalling proteins in MIA 
PaCa–2 the cells were stimulated with various chemicals, also called positive controls (Table 
2+9). The test was also to ascertain whether the antibodies corresponding to chosen proteins 
worked in MIA PaCa–2 cells. Cells were stimulated with Tumour necrosis factor (TNFα) for 
15 min (T1), A23187 + PMA for 30m min (T2), or A23187 for 4h (T3). WB was performed 
with 40 µg protein extract based on the results from testing cold 1× trypsin (chapter 4.2.6). 
ERK 1/2 was phosphorylated by all stimuli but was markedly stimulated by A23187+PMA, 
indicating that ERK 1/2 may be abundantly expressed in MIA PaCa–2 cells (Figure 24). It 
was confirmed that the ERK 1/2 Ab functioned as intended. Although, SAPK/JNK was 
phosphorylated in the control only, it was confirmed that the Ab functioned as intended. 
However, Ponceau red staining of the membrane shows equal loading of proteins (Figure 29 
– Appendix), thus, this deviation is unknown. p38 was phosphorylated by TNFα only, 
confirming that the Ab worked (Figure 24). eIF2α was phosphorylated in both the control and 
stimulated sample, indicating that this pathway is constitutively active in this cell line. Both 
epitopes of MYPT1 (Ser853/Ser696) were phosphorylated in both the control and stimulated 
sample (Figure 24). All tested antibodies worked, although p38 and SAPK/JNK Ab require 
the more sensitive SuperSignalTM West Femto Maximum Sensitivity Substrate for 
development of the membranes due to weak signal. For further WBs, including Abs not tested 
here, Femto Maximum Sensitivity Substrate was used only if detecting a signal with Pico 
Chemiluminescent Substrate was not successful.  
 
5.3.10 Optimisation of incubation time following sonoporation 
MIA PaCa–2 cells were sonoporated at High US (358 mW/cm2) with Sonazoid MBs and cells 
were harvested after 5 min, 1h, 2h, and 4h incubation following sonoporation as a check of 
phosphorylation kinetics in a few relevant pathways. Cells treated with MBs only was the 
control. Unfortunately, the protein concentration of cells from 4h incubation was too low to 
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be included in the WB due to sampling error. Therefore, only the control and cells from 5 
min, 1h and 2h incubation following sonoporated were included in the WB analysis. ERK 1/2 
was increasingly phosphorylated until 1h, indicating that ERK 1/2 phosphorylation increases 
until a certain time–point, then the signal fades (Figure 25). The amount of total protein is a 
bit higher in this sample, and this may be due to variation in loading. MLC was not 
phosphorylated until the 2h. sampling point, where the signal was strong, indicating a delayed 
reaction. MLC is phosphorylated downstream of Rho/ROCK. eIF2α had a time–dependent 
steady increase in phosphorylation (Figure 25). Many signalling proteins are downstream in 
extensive signalling cascades such as ERK 1/2, MLC and eIF2α. It is therefore natural to have 
a delayed response to stimuli. Clearly, it is essential to check signalling at other time–points 
following treatment, however, 2h incubation is a good starting point based on these results. 
Thereby, based on these results it was determined to proceed with 2h incubation time for 
further sonoporation studies of MIA PaCa–2.  
 
5.3.11 Sonoporated MIA PaCa–2 – viability  
MIA PaCa–2 cells, cultured in Petaka 3G bioreactors, were sonoporated at Low (3 mW/cm2), 
Medium (50mW/cm2) and High (358mW/cm2) US with and without Sonazoid MBs incubated 
for 2h following sonoporation. Cells were detached by ice–cold 1× trypsin and harvested for 
viability assays as described previously (chapter 3.3.1.1 – 3.3.1.3) Trypan blue counting was 
performed 2h after sonoporation. Cells for Hoechst 33342 and WST–1 were seeded 2h after 
sonoporation and then incubated for 24h further. The viability assays were started 2hours post 
sonoporation because cells were detached from the Petaka at this timepoint. Hoechst fixated 
cells were stored at 4oC for imaging and the cells for WST–1 was incubated for 2h before 
reading the absorption, as per chapter 3.3.1.2 and 3.3.1.3, respectively.  
The cells treated with US only differed in total cell count, of which the Low US sample had a 
higher cell count, and all of the samples had relatively few trypan blue stained cells (Figure 
26A). Of the samples treated with US and MBs the total cell count was again higher for Low 
US compared the other samples, and here more cells were stained by trypan blue, compared 
to the sample without MBs (Figure 26B). There is a trend of decreasing trypan blue stained 
cells with increasing US intensity. The uneven cell number may be a sampling error, or 
simply variation in cell growth in each Petaka. The use of this test to check for cavitation after 
sonoporation seems unreliable due to variations in growth prior to sonoporation (cell 
concentration prior to sonoporation is not known).    
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The Hoechst assay showed ta decreasing trend of percentage apoptosis in across all samples 
with/without MBs, with the exception of High US with MBs, which was higher (Figure 
26C+D), indicating that US and MBs is killing the cells at higher US intensities.  
The WST–1 metabolic assay showed a decrease in metabolic activity with increasing US 
intensity without MBs in the treated samples (Figure 26E), suggesting that higher US 
intensities in fact influence cell viability. This correlates with the Hoechst assay. The 
absorbance of the samples treated with US and MBs was very similar between the samples, 
and no difference was observed in the control (Figure 26F). Hence, no apparent effect on the 
cells metabolic ability caused by sonoporation was observed with MBs. There results indicate 
that US alone has an effect on MIA PaCa-2 cells, however, this needs to me confirmed.  
 
5.3.12 Sonoporated MIA PaCa–2 –  western blot 
5.3.12.1 MAPK pathway 
ERK 1/2 was weakly phosphorylated without MBs and a stronger signal with increasing US 
intensity with MBs. No phosphorylation of p38 or SAPK/JNK was detected (Figure 27). 
ERK 1/2, p38 and JNK are all MAP kinases, however they are not activated by the same 
cellular stimuli. The UPR, which has cross–talk with MAPKs, can be activated by ER–stress 
(32), that has been shown to be induced by sonoporation in leukaemia cells (MOLM–13)  
(20). It is not given that sonoporation will have the same effect on ERK 1/2 in pancreatic cells 
(MIA PaCa–2), nevertheless, the results indicate that ERK 1/2 was activated. Recalling that 
ERK 1/2, p38 and JNK had some activation in sonoporated MOLM–13 cells with MBs at 
higher US intensities (Figure 15), suggesting that sonoporation can induce phosphorylation in 
MAPKs. However, in MIA PaCa–2 the results deviate from the assumption that sonoporation 
can induce p38 and JNK signalling in MIA PaCa–2 cells as well. Importantly, the US 
intensities, referred to as Low, Medium and High US in studies of MOLM-13 and pancreatic 
cell lines were not the same. For MOLM-13 the US intensities were 74, 501 and 2079 
mW/cm2. For pancreatic cell lines the US intensities were 3, 50 and 358 mW/cm2. 
Consequently, High US (358 mW/cm2) used for pancreatic cells is quite low, compared to 
High US (2079 mW/cm2) used for MOLM-13. The US intensities used in diagnostic US 
range from 17 mW/cm2 to 720 mW/cm2, which is considered safe. For example for fetal 
imaging 94 mW/cm2 is used (23). Comparative to the diagnostic US the intensities used for 
MIA PaCa-2 is quite low and it is possible that a higher intensity is necessary to induce 
phosphorylation. Alternatively, it is possible that more than 40 µg protein is necessary to 
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detect a signal in p38 and JNK. However, the optimisation of WB, where Abs were tested, 
(Figure 26) indicated that 40 µg was sufficient to detect phosphorylation of these proteins. 
Importantly, conformation of the results is crucial. 
 
5.3.12.2 UPR pathway 
eIF2α was phosphorylated in all samples, suggesting that this is constitutively active (Figure 
27). However, there is no difference between the treated samples and the control, indicating 
activation by something else than sonoporation. Interestingly, in the optimisation of 
incubation time post sonoporation eIF2α was increasingly phosphorylated by high (358 
mW/cm2) and MBs, seen between 5 min and 2h after sonoporation (Figure 25), indication 
that phosphorylation of eIF2α is time–dependent. Here (Figure 27), samples for WB were 
only analysed after 2h. Together, these results prompt the need to investigate phosphorylation 
of eIF2α at multiple time–points following sonoporation to confirm 
 
5.3.12.3 JAK-STAT pathway 
STAT3 (Ser727) was phosphorylated in all samples (Figure 27). STAT3, which is a 
transcription factor,  is constitutively active in many cancers, including pancreatic cancer 
(40). STAT3 promote angiogenesis, survival, immune evasion, cell proliferation and 
migration/invasion, all of which are actions that aid in tumour progression. The constant 
activation of STAT3 across all samples correlate with a constitutively active STAT3. 
Considering that STAT3 (Ser727) also was constitutively activated in MOLM-13 at both 5 
min and 2h after sonoporation (Figure 15), suggests that sonoporation has little effect on this 
epitope of STAT3.  
 
5.3.12.4 PI3K–mTOR pathway 
S6 was increasingly phosphorylated at higher US intensities (Figure 27), indicating activation 
by sonoporation. S6 is downstream in the PI3K–mTOR pathway, which is normally activated 
by hormones, integrins and growth factors and mediates proliferation, growth, translation and 
survival (Figure 7) (42). Integrins are activated by mechanical stimuli (47), thus, it is possible 





5.3.12.5 Rho-ROCK pathway 
MLC was phosphorylated to some extent without MBs and a clear increase at High US with 
MBs (Figure 27). MYPT1 (Ser853) was weakly phosphorylated, while no phosphorylation 
was detected for MYPT1 (Ser696).  MLC and MYPT1 is part of the Rho/ROCK pathway, 
which mediates stress–fibre assembly and cell contraction (Figure 7) (43). MYPT1 is a part 
of MLCP (Figure 8), which inhibits the dephosphorylation of MLC, thereby increasing 
myosin II activity and stress–fibre formation (focal adhesions)  and contractility (44). Since 
there was not detected any phosphorylation of either epitopes of MYPT1, one can assume that 
MLC was not de–phosphorylated in the MIA PaCa–2 cells (Figure 27), which correlated with 
the strong phosphorylation of MLC at High US with MBs (Figure 27). This indicates that 
MLC and MYPT1 is not very sensitive to mechanical treatment (sonoporation).  
 
6.0 Concluding remarks and future directions 
 
The overall aim of this project was to elucidate the pathways activated by sonoporation in 
pancreatic cell lines by analysing post–translational modifications (i.e., phosphorylation). The 
long–term goal is to identify biomarkers for sonoporation that can be used to optimise 
sonoporation therapy.  
The investigation of protein signalling pathways in the AML cell line MOLM–13 showed that 
sonoporation affects cell viability and can induce phosphorylation of multiple signalling 
pathways. The most apparent effect on viability was found in samples treated with US and 
MBs. The number of dead cells, treated with MBs, increased with increasing US intensity, 
which correlated with a decrease in cell proliferation ability with increasing US intensity. The 
effect of sonoporation with MBs was also reflected in increased phosphorylation in apoptosis 
related proteins.  
The pancreatic cell lines were treated in the bioreactor Petaka G3 LOT, and in order to study 
cell signalling in adherent cells, they need to be detached. We used trypsin, which is a serine 
protease known to affect surface epitopes and intracellular signalling. It was confirmed that 
phosphorylation status differed when comparing cold and warm trypsinization with cell 
detachment by scraping. Phosphorylation of p38 was detected in cells detached with cold 1× 
trypsin, but not in cells detached with heated trypsin or by scaping. Non–enzymatic cell 
detachment should be further explored in signalling studies induced by sonoporation, since it 
eliminates the influence of enzymatic activation or de-activation of signalling proteins. In 
fact, Petakas are available with a built–in magnet used for cell detachment by scraping. A 
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more concentrated trypsin (10×) was also tested and, as expected, the cells detached faster, 
compared to 1×. However, it is not known whether cell detachment with 10× trypsin affects 
cell signalling or viability. We, therefore, used cold 1× trypsin from that point on. Faster cell 
detachment would be of great benefit when investigating multiple signalling pathways in 
several cell lines. Originally this project intended to investigate the sonoporation–induced 
signalling in the three pancreatic cell lines MIA PaCa–2, PANC–1 and BxPC3 to get a good 
representation of patient heterogeneity. However, since the test with 10×  trypsin was 
inconclusive, and since detaching PANC–1 and BxPC3 with cold 1× trypsin took too long 
only MIA PaCa-2 was further investigated. Future studies should include all three cell lines.  
We investigated change in phosphorylation status in MIA PaCa-2 cells 2h after sonoporation, 
however, considering that phosphorylation is a transient event further incubation times should 
be thoroughly tested. We found, for example that eIF2a had a time–dependent increase in 
phosphorylating. Although, a trend of decreasing metabolic activity, corresponding to an 
increase in number of apoptotic cells with increasing US intensity (without MBs) was 
identified in MIA PaCa-2 cells this needs to be further investigated to confirm the results. 
We have successfully identified sonoporation–induced signalling in the MAPK pathway 
(ERK 1/2), PI3K/mTOR pathway (S6) and Rho/ROCK pathway (MLC), but it would be 
advisable to investigate this further, including other post sonoporation incubation times. The 
lack of phosphorylation in the MAPKs p38 and JNK, as well as in both epitopes of MYPT1 
may be due to the fact that the phosphorylation occurs at other time–points. Additionally, it 
would be advisable to include higher US intensities in order to determine whether it affects 
the aforementioned pathways to a greater degree. Comparative studies should include non–
cancerous cells, such as endothelial cells and fibroblasts to elucidate how sonoporation affects 
healthy cells. 
 
Methodology for in vitro optimisation of sonoporation was developed. Using this 
methodology, we have identified several pathways activated by sonoporation that may have 
potential as biomarkers for PDAC that can be used to optimise sonoporation therapy. It was 
also found that higher US intensities and microbubbles may have an effect of cell viability, 
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Appendix A Antibodies 
 
Table 7: List of primary antibodies 
Antibody Epitope Molecular 
weight 
(kDa) 





51 38  Rabbit 9721 1:5000 
eIF2α mAb   38  Mouse 2103 1:5000 
Phospo–p44/42 
MAPK (ERK 1/2) 
XP® mAb 
Thr202 
44/42 D13.14.4E Rabbit 4370 1:2000 
Tyr204 
p44/42 MAP 
Kinase (ERK 1/2) 
mAb 




43 28B10 Mouse 9216 1:2000 
Tyr182 
p38 MAPK XP® 




 140  Rabbit 
4563 
 1:1000 
Ser696 5163 1:1000 
MYPT1 mAb  140 D6C1 Rabbit 8574  
Phospho–
SAPK/JNK mAb 
Thr183 46/54 G9 Mouse 9255 1:2000 Tyr185 
SAPK/JNK Ab  46/54  Rabbit 9252 1:2000 
Phospho–S6 
Ribosomal  
Protein XP® mAb  
Ser235 
32 D57.2.2E Rabbit 4858 1:2000 
Ser236 
S6 Ribosomal  
Protein mAb  32 54D2 Mouse 2317 1:1000 
Phospho–Stat3 
α/β mAb Tyr
705 79/86 D3A7 Rabbit 9145 1:2000 
Phospho–Stat3 
α/β pAb Ser
727 79/86  Rabbit 9134 1:1000 
Stat3 α/β mAb  79/86 124H6 Mouse 9139 1:1000 
Phospho–MLC 
mAb Ser
19 18  Mouse 3675 1:1000 
MLC Ab  18  Rabbit 3675 1:1000 
COX IV  17  Rabbit **ab16056 1:2000 






Table 8: Secondary antibodies 
Target Host Antibody 
format 
Specificity Conjugate Clonality Product 
number* 








*Jackson Immuno Research Laboratories Inc., West Grove, PA, USA  
 
 
Appendix B Positive controls 
 
Table 9: Function of positive controls 
Chemical Function 
A23187 (Calcimycin) Calcium Ionophore, highly selective for Ca2+ (85) 
Phorbol 12–myristate 13–
acetate (PMA) 
A phorbol ester that activates protein kinase C (PKC), 
ERK1/2 and p38 (86) 
TNFα Activates NF-κB pathway (including c-Jun, STATs, 
and nuclear hormone receptors) (87) 
 
 
Appendix C Optimisation of growth rate MIA PaCa-2 
  
Recipe for semi-automated identification of Hoechst 33342 stained cells. 
The contrast was adjusted, and the background was flattened to correct for illumination 
inhomogeneity. A dark texture filter was used to highlight dark components of the image via a 
grayscale closing method. A standard deviation filter was used to accentuate the cell edges by 
brightening pixels which have dissimilar neighbours. A range threshold was applied, holes 
were filled, and areas of 800 pixels or less were rejected to remove false positives. The 
percentage of selected pixels as a ratio of the original image size was considered the 
percentage surface area covered by cells 
 
Table 10: Recipe for Cell surface area. 
1- Adjust Contrast: Auto 
2- Flatten Background: 299 
3- Dark Texture: 83 
4- Standard deviation Filter: 15 
5- Range Threshold: 50 255 
6- Fill all holes 







Appendix D Ponceau red images from western blots 
 
Figure 28: Ponceau red stained membrane for 10×trypsin test (MLC). 
 
 
Figure 29: Ponceau red stained membrane (JNK) 
 
